CA2283159C - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor - Google Patents
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor Download PDFInfo
- Publication number
- CA2283159C CA2283159C CA002283159A CA2283159A CA2283159C CA 2283159 C CA2283159 C CA 2283159C CA 002283159 A CA002283159 A CA 002283159A CA 2283159 A CA2283159 A CA 2283159A CA 2283159 C CA2283159 C CA 2283159C
- Authority
- CA
- Canada
- Prior art keywords
- sustained release
- formulation
- nicotinic acid
- set forth
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Abstract
An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent.
The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally", that is in the evening or at night.
The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally", that is in the evening or at night.
Description
2 PCT/US98/04590 NICOTINIC ACID COMPOSITIONS FOR TREATING
HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
Field of the Invention This invention generally relates to compositions of nicotinic acid useful for treating hyperlipidemia and methods of treating hyperlipidemia employing such compositions. More particularly, the present invention employs a composition of nicotinic acid, derivatives and mixtures thereof, and a swelling agent to form a time release sustaining composition for nocturnal or evening dosing. Specifically, the present invention employs a composition of nicotinic acid and hydroxypropyl methylcellulose to treat hyperlipidemia in a once per day oral dosage form given during the evening hours.
Background Nicotinic acid has been used for many years in the treatment of hyperlipidemia. This compound has long been known to exhibit the beneficial effects of reducing total cholesterol, low density lipoproteins or "LDL cholesterol", triglycerides and apolipoprotein a (Lp(a)) in the human body, while increasing desirable high density lipoproteins or "HDL
cholesterol".
Nicotinic acid has normally been adtninistered three times per day after meals. This dosing regimen is known to provide a very beneficial effect on blood lipids as discussed in Knopp et al;
"Contrasting Effects of Unmodified and Time-Release Forms of Niacin on Lipoproteins in Hyperlipidemic Subjects: Clues to Mechanism of Action of Niacin"; Metabolism 34/7, 1985, page 647. The chief advantage of this profile is the ability of nicotinic acid to decrease total cholesterol, LDL cholesterol, triglycerides and Lp(a) while increasing HDL
particles. While such a regimen does produce beneficial effects, cutaneous flushing and the like still often occurs in the hyperlipidemics to whom the compound is administered.
In order to avoid or reduce the cutaneous flushing, a number of materials have been suggested for administration with an effective antihyperlipidemic amount of nicotinic acid, including guar gum in U.S. Pat. No. 4,965,252, and mineral salts, as disclosed in U.S. Pat. No.
5,023,245; or inorganic magnesium salts as reported in U.S. Pat. No.
4,911,917. These materials have been reported to avoid or reduce the cutaneous flushing side effect commonly associated with nicotinic acid treatment.
Another method of avoiding or reducing the side effects associated with immediate release niacin is the use of sustained release formulations. Sustained release formulations are designed to siowly release the compound from the tablet or capsule. The slow drug release reduces and prolongs blood levels of drug and thus minimizes the side effects. Sustained release formulations of niacin have been developed, such as NicobidT"' capsules (Rhone-Poulenc Rorer), Endur-acinTM
(Innovite Corporation) and Pat. No. 5,126,145 which describes a sustained release niacin formulation containing two different types of hydroxypropyl methylcellulose and a hydrophobic component.
Studies in hyperlipidemic patients have been conducted with a number of sustained release niacin products. These studies have demonstrated that the sustained release products do not have the same advantageous lipid altering effects as immediate release niacin, and in fact often have a worse side effect profile compared to the immediate release product. The major disadvantage of the sustained release formulations, as can be seen in Knopp et al., 1985, is the significantly lower . ._ ._ , WO 98/39002 PCT/US98/0,4590
HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
Field of the Invention This invention generally relates to compositions of nicotinic acid useful for treating hyperlipidemia and methods of treating hyperlipidemia employing such compositions. More particularly, the present invention employs a composition of nicotinic acid, derivatives and mixtures thereof, and a swelling agent to form a time release sustaining composition for nocturnal or evening dosing. Specifically, the present invention employs a composition of nicotinic acid and hydroxypropyl methylcellulose to treat hyperlipidemia in a once per day oral dosage form given during the evening hours.
Background Nicotinic acid has been used for many years in the treatment of hyperlipidemia. This compound has long been known to exhibit the beneficial effects of reducing total cholesterol, low density lipoproteins or "LDL cholesterol", triglycerides and apolipoprotein a (Lp(a)) in the human body, while increasing desirable high density lipoproteins or "HDL
cholesterol".
Nicotinic acid has normally been adtninistered three times per day after meals. This dosing regimen is known to provide a very beneficial effect on blood lipids as discussed in Knopp et al;
"Contrasting Effects of Unmodified and Time-Release Forms of Niacin on Lipoproteins in Hyperlipidemic Subjects: Clues to Mechanism of Action of Niacin"; Metabolism 34/7, 1985, page 647. The chief advantage of this profile is the ability of nicotinic acid to decrease total cholesterol, LDL cholesterol, triglycerides and Lp(a) while increasing HDL
particles. While such a regimen does produce beneficial effects, cutaneous flushing and the like still often occurs in the hyperlipidemics to whom the compound is administered.
In order to avoid or reduce the cutaneous flushing, a number of materials have been suggested for administration with an effective antihyperlipidemic amount of nicotinic acid, including guar gum in U.S. Pat. No. 4,965,252, and mineral salts, as disclosed in U.S. Pat. No.
5,023,245; or inorganic magnesium salts as reported in U.S. Pat. No.
4,911,917. These materials have been reported to avoid or reduce the cutaneous flushing side effect commonly associated with nicotinic acid treatment.
Another method of avoiding or reducing the side effects associated with immediate release niacin is the use of sustained release formulations. Sustained release formulations are designed to siowly release the compound from the tablet or capsule. The slow drug release reduces and prolongs blood levels of drug and thus minimizes the side effects. Sustained release formulations of niacin have been developed, such as NicobidT"' capsules (Rhone-Poulenc Rorer), Endur-acinTM
(Innovite Corporation) and Pat. No. 5,126,145 which describes a sustained release niacin formulation containing two different types of hydroxypropyl methylcellulose and a hydrophobic component.
Studies in hyperlipidemic patients have been conducted with a number of sustained release niacin products. These studies have demonstrated that the sustained release products do not have the same advantageous lipid altering effects as immediate release niacin, and in fact often have a worse side effect profile compared to the immediate release product. The major disadvantage of the sustained release formulations, as can be seen in Knopp et al., 1985, is the significantly lower . ._ ._ , WO 98/39002 PCT/US98/0,4590
-3-reduction in triglvicerides (-2% for the sustained release versus -38% for the immediate release) and lower increase in HDL cholesterol, represented at HDL, particles which are known by the art to be most beneficial, (-5% for the sustained release versus +37% for the immediate release).
Additionally, sustained release niacin formulations have been noted as causiiig greater incidences of liver toxicity as described in Henken et al (Am J Med 91:l 991 1991) and Dalton et al (Am J Med 93: 102 1992). There is also great concern regarding the potential of these formulations in disrupting glucose metabolism and uric acid levels.
In a recent edition of the JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(JAMA), an articles appeared which presented research results investigating the liver toxicitv problems associated with a sustained release form of nicotinic acid. "A
Comparison of the Efficacy and Toxic Effects of Sustained- vs. Immediate-Release Niacin in Hypercholsterolemic Patients", McKenney et al., JAMA, Vol. 271, No. 9, March 2, 1994, page 672.
The article presented a study of twenty-three patients. Of that number, 12 or 52 percent were forced to withdraw because liver function tests (LFTs) increased indicating potential liver damage. The conclusion of the authors of that article was that the sustained release form of niacin "should be restricted from use."
A similar conclusion was reached in an article authored by representatives of the Food and Drug Administration and entitled "Hepatic Toxicity of Unmodified and Time-Release Preparations of Niacin", Rader, et al., THE AMERICAN JOURNAL OF MEDICINE, Vol. 92, January 1992, page 77. Because of these studies and similar conclusions drawn by other health care professionals, the sustained release forms of niacin have experienced limited utilizatio.n.
Therefore, it can be seen from the scientific literature that there is a need for development of a sustained release niacin formulation and a method of delivering said formulation which would provide hyperlipidemic patients with "balanced lipid alteration", i.e.
reductions in total cholesterol,
Additionally, sustained release niacin formulations have been noted as causiiig greater incidences of liver toxicity as described in Henken et al (Am J Med 91:l 991 1991) and Dalton et al (Am J Med 93: 102 1992). There is also great concern regarding the potential of these formulations in disrupting glucose metabolism and uric acid levels.
In a recent edition of the JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(JAMA), an articles appeared which presented research results investigating the liver toxicitv problems associated with a sustained release form of nicotinic acid. "A
Comparison of the Efficacy and Toxic Effects of Sustained- vs. Immediate-Release Niacin in Hypercholsterolemic Patients", McKenney et al., JAMA, Vol. 271, No. 9, March 2, 1994, page 672.
The article presented a study of twenty-three patients. Of that number, 12 or 52 percent were forced to withdraw because liver function tests (LFTs) increased indicating potential liver damage. The conclusion of the authors of that article was that the sustained release form of niacin "should be restricted from use."
A similar conclusion was reached in an article authored by representatives of the Food and Drug Administration and entitled "Hepatic Toxicity of Unmodified and Time-Release Preparations of Niacin", Rader, et al., THE AMERICAN JOURNAL OF MEDICINE, Vol. 92, January 1992, page 77. Because of these studies and similar conclusions drawn by other health care professionals, the sustained release forms of niacin have experienced limited utilizatio.n.
Therefore, it can be seen from the scientific literature that there is a need for development of a sustained release niacin formulation and a method of delivering said formulation which would provide hyperlipidemic patients with "balanced lipid alteration", i.e.
reductions in total cholesterol,
-4-LDL cholesterol, triglycerides and Lp(a) as well as increases in HDL
particles, with an acceptable safety profile, especially as regards liver toxicity and effects on glucose metabolism and uric acid levels.
SUMMARY OF THE INVENTION
In brief, the present invention alleviates and overcomes certain of the above-identified problems and shortcomings of the present state of nicotinic acid therapy through the discovery of novel nicotinic acid formulations and methods of treatment.
The present invention seeks to provide a composition of nicotinic acid or any compound which is metabolized by the body to form nicotinic acid for treating hyperlipidemia.
The present invention also seeks to provide a composition as above, which has a time release sustaining characteristic.
The present invention also seeks to provide a method for employing a composition as above, for treating hyperlipidemia, which results in little or no liver damage.
At least one or more of the foregoing, together with the advantages thereof over the known art relating to the treatment of hyperlipidemia, which shall become apparent from the specification which follows, are accomplished by the invention as hereinafter described.
-4a -In accordance with one aspect of the invention there is provided an oral dosage pharmaceutical composition for daily treatment of hyperlipidemia in a patient without inducing treatment-limiting liver damage, said composition comprising an effective antihyperlipidemic amount of nicotinic acid for use as an oral dose once per day during the evening or at night, or before bedtime, as a single dose, wherein the nicotinic acid is combined with at least one pharmaceutically acceptable carrier comprising a swelling agent in a total amount which functions as a controlled release agent, to form an oral sustained release solid dosage form, and wherein the oral sustained release solid dosage form does not contain an internal hydrophobic component, said, single daily oral dose causing little or no serious damage to the liver of the patient, said nicotinic acid being present in said dosage form in milled agglomerates of the nicotinic acid, a portion of the total swelling agent, and a granulation binder, the agglomerates having been milled to a uniform particle size distribution, and said milled agglomerates being blended, in said dosage form, with the remaining portion of the total amount of swelling agent and an external lubricant.
In accordance with another aspect of the invention there is provided use of a composition of the invention for treating hyperlipidemia in a patient without inducing treatment-limiting (i) hepatotoxicity and (ii) abnormalities in uric acid levels or glucose levels or both.
In accordance with still another aspect of the invention there is provided a method of manufacturing a base granulation for producing a sustained release nicotinic acid solid dosage form, said method comprising:
(a) forming a wet granulation which consists essentially of nicotinic acid, a portion of a total amount of a swelling agent which functions as a controlled release agent, and a granulation binder;
(b) drying the wet granulation to form dry granules;
- 4b -(c) milling the dry granules to obtain a substantially uniform particle size distribution;
(d) dry blending the milled dry granules, the remaining portion of the total amount of swelling agent, and an external lubricant to form a final dosage blend; and (e) forming the sustained release nicotinic acid solid dosage form from the final dosage blend.
In particular embodiments the present invention provides an improved antihyperlipidemia composition of the oral type employing an effective antihyperlipidemic amount of nicotinic acid, wherein the improvement comprises compounding the nicotinic acid with from about 5% to about 50%
parts by weight of hydroxypropyl methylcellulose per hundred parts by weight of tablet or formulation.
The present invention also provides an orally administered antihyperlipidemia composition which comprises from about 30% to about 90% parts by weight of nicotinic acid; and, from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose.
The present invention also includes a method of treating hyperlipidemia in a hyperlipidemic. The method comprises the steps of forming a composition which comprises an effective antihyperlipidemic amount of nicotinic acid and an amount of excipients to provide sustained release of drug. The method also includes the step of orally administering the composition to the hyperlipidemic nocturnally.
particles, with an acceptable safety profile, especially as regards liver toxicity and effects on glucose metabolism and uric acid levels.
SUMMARY OF THE INVENTION
In brief, the present invention alleviates and overcomes certain of the above-identified problems and shortcomings of the present state of nicotinic acid therapy through the discovery of novel nicotinic acid formulations and methods of treatment.
The present invention seeks to provide a composition of nicotinic acid or any compound which is metabolized by the body to form nicotinic acid for treating hyperlipidemia.
The present invention also seeks to provide a composition as above, which has a time release sustaining characteristic.
The present invention also seeks to provide a method for employing a composition as above, for treating hyperlipidemia, which results in little or no liver damage.
At least one or more of the foregoing, together with the advantages thereof over the known art relating to the treatment of hyperlipidemia, which shall become apparent from the specification which follows, are accomplished by the invention as hereinafter described.
-4a -In accordance with one aspect of the invention there is provided an oral dosage pharmaceutical composition for daily treatment of hyperlipidemia in a patient without inducing treatment-limiting liver damage, said composition comprising an effective antihyperlipidemic amount of nicotinic acid for use as an oral dose once per day during the evening or at night, or before bedtime, as a single dose, wherein the nicotinic acid is combined with at least one pharmaceutically acceptable carrier comprising a swelling agent in a total amount which functions as a controlled release agent, to form an oral sustained release solid dosage form, and wherein the oral sustained release solid dosage form does not contain an internal hydrophobic component, said, single daily oral dose causing little or no serious damage to the liver of the patient, said nicotinic acid being present in said dosage form in milled agglomerates of the nicotinic acid, a portion of the total swelling agent, and a granulation binder, the agglomerates having been milled to a uniform particle size distribution, and said milled agglomerates being blended, in said dosage form, with the remaining portion of the total amount of swelling agent and an external lubricant.
In accordance with another aspect of the invention there is provided use of a composition of the invention for treating hyperlipidemia in a patient without inducing treatment-limiting (i) hepatotoxicity and (ii) abnormalities in uric acid levels or glucose levels or both.
In accordance with still another aspect of the invention there is provided a method of manufacturing a base granulation for producing a sustained release nicotinic acid solid dosage form, said method comprising:
(a) forming a wet granulation which consists essentially of nicotinic acid, a portion of a total amount of a swelling agent which functions as a controlled release agent, and a granulation binder;
(b) drying the wet granulation to form dry granules;
- 4b -(c) milling the dry granules to obtain a substantially uniform particle size distribution;
(d) dry blending the milled dry granules, the remaining portion of the total amount of swelling agent, and an external lubricant to form a final dosage blend; and (e) forming the sustained release nicotinic acid solid dosage form from the final dosage blend.
In particular embodiments the present invention provides an improved antihyperlipidemia composition of the oral type employing an effective antihyperlipidemic amount of nicotinic acid, wherein the improvement comprises compounding the nicotinic acid with from about 5% to about 50%
parts by weight of hydroxypropyl methylcellulose per hundred parts by weight of tablet or formulation.
The present invention also provides an orally administered antihyperlipidemia composition which comprises from about 30% to about 90% parts by weight of nicotinic acid; and, from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose.
The present invention also includes a method of treating hyperlipidemia in a hyperlipidemic. The method comprises the steps of forming a composition which comprises an effective antihyperlipidemic amount of nicotinic acid and an amount of excipients to provide sustained release of drug. The method also includes the step of orally administering the composition to the hyperlipidemic nocturnally.
-5-A method of treating hyperlipidemia in a hyperlipidemic according to the invention, comprises dosing the hyperlipidemic with an effective antihyperlipidemic amount of nicotinic acid or compound metabolized to nicotinic acid by the body. The dose is given once per day in the evening or at night, combined with a pharmaceutically acceptable carrier to produce a significant reduction in total and LDL cholesterol as well as a significant reduction in triglycerides and Lp(a), with a significant increase in HDL
cholesterol.
The above features and advantages of the present invention will be better understood with reference to the following detailed description and examples.
It should also be understood that the particular methods and formulations illustrating the present invention are exemplary only and not to be regarded as limitations of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
By way of illustrating and providing a more complete appreciation of the present invention and many of the attendant advantages thereof, the following detailed description and examples are given concerning the novel methods and formulations.
The present invention employs nicotinic acid or a compound other than nicotinic acid itself which the body metabolizes into nicotinic acid, thus producing the same effect as described herein.
cholesterol.
The above features and advantages of the present invention will be better understood with reference to the following detailed description and examples.
It should also be understood that the particular methods and formulations illustrating the present invention are exemplary only and not to be regarded as limitations of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
By way of illustrating and providing a more complete appreciation of the present invention and many of the attendant advantages thereof, the following detailed description and examples are given concerning the novel methods and formulations.
The present invention employs nicotinic acid or a compound other than nicotinic acid itself which the body metabolizes into nicotinic acid, thus producing the same effect as described herein.
-6-The other compounds specifically include, but are not limited to the following: nicotinyl alcohol tartrate, d-glucitol hexanicotinate, aluminum nicotinate, niceritrol and d,1-alpha-tocopheryl nicotinate. Each such compound will be collectively referred to hereinbelow by "nicotinic acid."
As stated hereabove, nicotinic acid has been employed in the past for the treatment of hyperlipidemia, which condition is characterized by the presence of excess fats such as cholesterol and triglycerides, in the blood stream. According to the present invention, a sustained release composition of nicotinic acid is prepared as an example. By "sustained release" it is understood to mean a composition which when orally administered to a patient to be treated, the active ingredient will be released for absorption into the blood stream over a period of time. For exampled, it is preferred that in a dosage of about 1500 milllgrams (hereinafter "mgs") of nicotinic acid, approximately 100 percent of the nicotinic acid will be released into the blood stream in about 4 to about 24 hours.
The specified sustained releases composition according to the present invention employs an effective antihyperlipidemic amount of nicotinic acid. By "effective antihyperlipidemic amount" it is understood to mean an amount which when orally administered to a patient to be treated, will have a beneficial effect upon the physiology of the patient, to include at least some lowering of total cholesterol, LDL cholesterol, triglycerides and Lp(a) and at least some increase in HDL cholesterol in the patient's blood stream. An exemplary effective antihyperlipidemic amount of nicotinic acid would be from about 250 mgs to about 3000 mgs of nicotinic acid to be administered according to the invention as will be more fully described hereinbelow. This amount will vary dependent upon a number of variables, including the psychological needs of the patient to be treated.
Preferably, there is also included in the sustained release composition according to the present invention, a swelling agent which is compounded with the nicotinic acid, such that when r r ,
As stated hereabove, nicotinic acid has been employed in the past for the treatment of hyperlipidemia, which condition is characterized by the presence of excess fats such as cholesterol and triglycerides, in the blood stream. According to the present invention, a sustained release composition of nicotinic acid is prepared as an example. By "sustained release" it is understood to mean a composition which when orally administered to a patient to be treated, the active ingredient will be released for absorption into the blood stream over a period of time. For exampled, it is preferred that in a dosage of about 1500 milllgrams (hereinafter "mgs") of nicotinic acid, approximately 100 percent of the nicotinic acid will be released into the blood stream in about 4 to about 24 hours.
The specified sustained releases composition according to the present invention employs an effective antihyperlipidemic amount of nicotinic acid. By "effective antihyperlipidemic amount" it is understood to mean an amount which when orally administered to a patient to be treated, will have a beneficial effect upon the physiology of the patient, to include at least some lowering of total cholesterol, LDL cholesterol, triglycerides and Lp(a) and at least some increase in HDL cholesterol in the patient's blood stream. An exemplary effective antihyperlipidemic amount of nicotinic acid would be from about 250 mgs to about 3000 mgs of nicotinic acid to be administered according to the invention as will be more fully described hereinbelow. This amount will vary dependent upon a number of variables, including the psychological needs of the patient to be treated.
Preferably, there is also included in the sustained release composition according to the present invention, a swelling agent which is compounded with the nicotinic acid, such that when r r ,
-7-the composition is orally administered to the patient, the swelling agent will swell over time in the patient's gastrointestinal tract, and release the active nicotinic acid, or a compound which produces nicotinic acid into the gastrointestinal system for absorption into the blood stream. over a period of time. As is known in the art, such swelling agents and amounts thereof, may be preselected in order to control the time release of the active ingredient.
Such swelling agents include, but are not lirnited to, polymers such as sodium carboxymethylcellulose and ethylcellulose and waxes such as bees wax and natural materials such as gums and gelatins or mixtures of any of the above. Because the amount of the swelling agent will vary depending upon the nature of the agent, the time release needs of the patient and the like, it is preferred to employ amounts of the agent which will accomplish the objects of the invention.
An exemplary and preferred swelling agent is hydroxypropyl methyleellulose, in an amount ranging from about 5% to about 50% parts by weight per 100 parts by weight of tablet or formulation. The preferred example will ensure a sustained time release over a period of approximately 4-24 hours as demonstrated by in vitro dissolution techniques known to the art.
A binder may also be employed in the present compositions. While any known binding material is useful in the present invention, it is preferred to employ a material such as one or more of a group of polymers having the repeating unit of 1-ethenyl-2-pyrrolidinone.
These polymers generally have molecular weights of between about 10,000 and 700,000, and are also known as "povidone"_ Amounts of the binder material will of course, vary depending upon the nature of the binder and the amount of other ingredients of the composition. An exemplary amount of povidone in the present compositions would be from about 1% to about 5% by weight of povidone per 100 parts by weight of the total formulation.
Such swelling agents include, but are not lirnited to, polymers such as sodium carboxymethylcellulose and ethylcellulose and waxes such as bees wax and natural materials such as gums and gelatins or mixtures of any of the above. Because the amount of the swelling agent will vary depending upon the nature of the agent, the time release needs of the patient and the like, it is preferred to employ amounts of the agent which will accomplish the objects of the invention.
An exemplary and preferred swelling agent is hydroxypropyl methyleellulose, in an amount ranging from about 5% to about 50% parts by weight per 100 parts by weight of tablet or formulation. The preferred example will ensure a sustained time release over a period of approximately 4-24 hours as demonstrated by in vitro dissolution techniques known to the art.
A binder may also be employed in the present compositions. While any known binding material is useful in the present invention, it is preferred to employ a material such as one or more of a group of polymers having the repeating unit of 1-ethenyl-2-pyrrolidinone.
These polymers generally have molecular weights of between about 10,000 and 700,000, and are also known as "povidone"_ Amounts of the binder material will of course, vary depending upon the nature of the binder and the amount of other ingredients of the composition. An exemplary amount of povidone in the present compositions would be from about 1% to about 5% by weight of povidone per 100 parts by weight of the total formulation.
-8-Processing aids such as lubricants, including stearic acid, may also be employed, as is known in the art. An exemplary amout of stearic acid in the present compositions would be from about 0.5% to about 2.0% by weight per 100 parts by weight of tablet or formulation.
Examples of various embodiments of the present invention will now be further illustrated with reference to the following examples.
General Experimental In order to demonstrate the effectiveness of the compositions and method of the present invention over known antihyperlipidemia compositions and methods heretofore known in the art, a number of substantially identical composition were prepared according to the disclosure hereinabove. The composition and ingredients and amounts are listed in TABLE 1 A hereinbelow.
TABLE IA
Test Tablet Composition Ingredient 375 mg 500 mg 750 mg Nicotinic Acid 375.0 500.0 750.0 Hyroxypropyl 188.7 203.0 204.7 methylcellulose Povidone 12.9 17.2 25.9 Stearic Acid 5.8 7.3 9.9 TOTAL 582.4 mg 727.5 mg 990.5 mg The ingredients were compounded together to form a tablet. More specifically, Niaspan once-daily tablets in accordance with the present invention utilize a hydrophilic matrix controlled drug delivery system. This is a dynamic system composed of polymer wetting, polymer hydration and polymer disintegration/dissolution. The mechanism by which drug release is controlled depends on, for example, initial polymer wetting, expansion of the gel layer, tablet erosion and niacin solubility. Aft.er initial wetting, the hydrophyllic polymer starts to partially hydrate, forming a gel layer. As water permeates into the tablet increasing the thickness of the gel layer, drug T ~. ,
Examples of various embodiments of the present invention will now be further illustrated with reference to the following examples.
General Experimental In order to demonstrate the effectiveness of the compositions and method of the present invention over known antihyperlipidemia compositions and methods heretofore known in the art, a number of substantially identical composition were prepared according to the disclosure hereinabove. The composition and ingredients and amounts are listed in TABLE 1 A hereinbelow.
TABLE IA
Test Tablet Composition Ingredient 375 mg 500 mg 750 mg Nicotinic Acid 375.0 500.0 750.0 Hyroxypropyl 188.7 203.0 204.7 methylcellulose Povidone 12.9 17.2 25.9 Stearic Acid 5.8 7.3 9.9 TOTAL 582.4 mg 727.5 mg 990.5 mg The ingredients were compounded together to form a tablet. More specifically, Niaspan once-daily tablets in accordance with the present invention utilize a hydrophilic matrix controlled drug delivery system. This is a dynamic system composed of polymer wetting, polymer hydration and polymer disintegration/dissolution. The mechanism by which drug release is controlled depends on, for example, initial polymer wetting, expansion of the gel layer, tablet erosion and niacin solubility. Aft.er initial wetting, the hydrophyllic polymer starts to partially hydrate, forming a gel layer. As water permeates into the tablet increasing the thickness of the gel layer, drug T ~. ,
-9-diffuses out of the gel layer. As the outer layer of the tablet becomes fully hydrated it erodes. It is believed that this erosion results in additional drug release. The controlled release from this matrix delivery system can be modified depending on the type and molecular weight of hydrophilic polymer used.
A Niaspan formulation consists of Niacin, Methocel E l OM Premium, Povidone and Hystrene 5016 (stearic acid). Methocel(g E I OM Premium is utilized as a controlled-release agent in the Niaspan formulation. Methocel is a partly 0-methylated and O-(2-hvdroxypropylated) cellulose and is available in several grades which vary in terms of viscosity and degree of substitution. Methocel is manufactured by Dow Chemical.
Povidone K90 is employed as a granulating/binding agent in a Niaspan formulation.
Povidone is a synthetic polymer consisting of linear 1-vinyl-2-pyrrolidone groups, the degree of polymerization of which results in polymers of various molecular weights, or as indicated above.
It is characterized by its viscosity in aqueous solution, relative to that of water, expressed as a K-value, ranging from 10-120. Povidone K90 has an approximate molecular weight of 1,000,000.
Povidone is a hygroscopic, water soluble material. Povidone K90 present in a Niaspan formulation is manufactured by ISP (International Specialty Products).
Hystrene 5016 is utilized as an external lubricant in the Niaspang forumation. Hystrene 5016 is a mixture of stearic acid and palmitic acid. The content of stearic acid is not less than about 40.0%
and the sum of the two acids is not less than about 90.0%. Hystrene 5016 is manufactured by Witco.
Refer to Table IB
for Niaspan forumlation details.
Qualitatively, the four tablet strength formulations are identical. The major component of each formulation is a granulated mixture of Niacin, Methocel EIOM and Povidone K90. The granulation process improves compression properties.
A Niaspan formulation consists of Niacin, Methocel E l OM Premium, Povidone and Hystrene 5016 (stearic acid). Methocel(g E I OM Premium is utilized as a controlled-release agent in the Niaspan formulation. Methocel is a partly 0-methylated and O-(2-hvdroxypropylated) cellulose and is available in several grades which vary in terms of viscosity and degree of substitution. Methocel is manufactured by Dow Chemical.
Povidone K90 is employed as a granulating/binding agent in a Niaspan formulation.
Povidone is a synthetic polymer consisting of linear 1-vinyl-2-pyrrolidone groups, the degree of polymerization of which results in polymers of various molecular weights, or as indicated above.
It is characterized by its viscosity in aqueous solution, relative to that of water, expressed as a K-value, ranging from 10-120. Povidone K90 has an approximate molecular weight of 1,000,000.
Povidone is a hygroscopic, water soluble material. Povidone K90 present in a Niaspan formulation is manufactured by ISP (International Specialty Products).
Hystrene 5016 is utilized as an external lubricant in the Niaspang forumation. Hystrene 5016 is a mixture of stearic acid and palmitic acid. The content of stearic acid is not less than about 40.0%
and the sum of the two acids is not less than about 90.0%. Hystrene 5016 is manufactured by Witco.
Refer to Table IB
for Niaspan forumlation details.
Qualitatively, the four tablet strength formulations are identical. The major component of each formulation is a granulated mixture of Niacin, Methocel EIOM and Povidone K90. The granulation process improves compression properties.
-10-TABLE IB
Niaspan Tablet Formulations Niaspang Product 375mg Tablets 500mg Tablets .750mg Tablets 1000mg Tablets Fonnulation. % Tablets Niacin 64.4 70.5 77.4 83.1 Methocel E l OM 7.4 8.1 8.9 9.5 Premium (intragranular) 2.2 2.4 2.7 2.9 Povidone K90 Methoccl E l OM
25.0 18.0 10.0 3.5 Prcmium (Extragranular) Hvstrcnc 5016 1.0 1.0 1.0 1.0 (Stearic Acid) Table weight, mg 582.5 709.5 968.6 1203.6 =
Niaspan formulations are presented in white caplet shape tablets. Caplet dimensions differ with respect to product strength. The 375mg and 500mg Niaspan tablets are compressed with tooling measuring approximately 0.687" in length x 0.281" by width. The length and width of the 750mg and 1000mg tooling measures approximately Ø750" x 0.320".
Target tablet weight and hardness dictate thickness across the four Niaspan products. The production of the Niaspan tablets will now be described generally as set forth below.
Niaspan Granulation Process Flow Chart Raw Materials Process Flow Equipment Niacin Granulate High shear granulator Povidone K90 (Littleford FM 130) Methocel E l OM
(Intragranular) Purfied Water Dry Fluid bed drier (Glatt fluid bed drier) Parcel size reduction Mill (Kemutec Betagrind) Niaspan@ Granulation Process Description Niaspan granulation raw materials are dispensed and granulated in a high shear granulator. The wet granules are sieved into a fluid bed drier and are dried.
When the drying process is complete, the granules are milled. Milling ensures uniform particle size distribution throughout the Niaspan granulation.
Niaspan Tablet Process Flow Chart Raw Materials Process Flow Eguioment NiaspanQ Tablet 13lend Mcthoccl 13lend Milled Niaspan(P.) granules Blcnder E l OM with (Patterson-Kelley (Extragranular) extragranular Methocel E l OM and V-Blender) Hystrene ] lystrenc 5016 5016 (Stearic acid) Niaspang T'able Manufacture Compress NiaspanO Tablet Blend Rotary tablet press NiasRan Tablet Process Description A Niaspan tablet blend is manufactured by blending the Niaspan granulation, extragranular Methocel EIOM and Hystrene 5016. The quantities of each Niaspan tablet blend I I I
component will depend on the particular Niaspan dose being manufactured (refer to Table IB).
A Niaspan tablet blend is compressed to form Niaspan tablets. Niaspan tablet physical properties will vary depending on the particular Niaspan dose being manufactured.
Production of Niaspan tablets will now be discussed in greater detail. The initial stage of manufacturing is the same for all four tablet strengths of Niaspan (375, 500, 750 and l 000mg). One batch of Niaspan granulation is comprised of four individual 40.0kg units of granulation which are processed separately, but under like conditions. The four individual granulations are sampled and tested individually and subsequently released for blending. The base granulation is not strength specific and may be used to manufacture any tablet strength of Niaspan .
The ingredients in the base granulation are set froth in Table IC below:
TABLE IC
Component Function Quantity pcr % per Quantity per kilogram kilogram 160.00 kg granulation (kg) granulation batch (kg) (%) Niacin, tISP Drug Substance F 0.87 F 87.00 139.20 inder F 0.03 3.00 4.80 Povidinc, UPS B
F
Methoccl USP, Controlled 0.10 10.00 16.00 E l OM Premium Release Agent CR Grade 0.00' Purified Water, Granulation 0.00' 48 USP' Rcagcnt Total 160 "Purified Water, USP is used as granulation reagent and does not appear in the finished granulation.
Raw materials are quantatively dispensed into appropriately labeled double polyethylene-lined containers using calibrated scales. Purified Water, USP is dispensed into an appropriate vessel from which it is later pumped during the wet-massing operation.
A Littleford FM130 granulator is charged with approximately one half of the Niacin, USP
required for the process unit (-17.4 kg) followed by about 4.00kg of Methocel, USP EIOM
Premium CR Grade; about 1.20kg of Povidine, USP; and the balance of the Niacin, SP
(-17.40kg). The powder bed is dry mixed in the Littleford FM130 granulator, with choppers on, for approximately 1 minute. At the completion of the 1-minute pre-mix cycle, about 12.0 0.05kg SUBSTITUTE SHEET (RULE 26) ,. , of Purified Water, USP are sprayed onto the powder bed at a rate of about 2.40 0.24kg/minute.
Immediately following the addition of the Purified Water, USP, the unit is granulated for about minutes.
The granulated unit is discharged into double polyethylene-lined containers and then 5 manually loaded into a Glatt bowl while being passed through a #4 mesh screen. The Glatt bowl is loaded into a Glatt TFO-60 fluid-bed drier with an inlet air temperature setting of about 70 Ct5 C. The unit is dried until a moisture level of < 1.0% is obtained as determined using a Computrac Moisture Analyzer, model MA5A. The dried granulation is discharged into appropriately labeled, double polyethylene-lined drums and reconciled.
The dried and reconciled granulation is passed through a Kemutec BetaGrind mill equipped with a 1.5mm screen and running at approximately 1500 RPM. The milled granulation is collected into appropriately labeled, double polyethylene-lined drums and reconciled. The milled granulation is sampled and tested by Quality Control and released prior to further processing.
The released granulation units are charged to a Patterson-Kelley 20 ft; V-blender after which they are blended together for about 10 1 minutes and then discharged to appropriately labeled, double polyethylene-lined containers.
As stated above, Niaspan tablets are formulated from a common granulation which is blended with appropriate quantities of Methocel, USP E l OM Premium CR Grade and Stearic Acid, NF to achieve the final dosage forrnulation. Tables IA and IB describe the formulation for each Niaspan tablet strength, 3 75mg, 500mg, 750mg and 1000mg, respectively.
Two study groups consisting of eleven and fourteen patients each were formed.
Blood samples were taken from the patients, and tested for total cholesterol, LDL
cholesterol, triglycerides and HDL cholesterol to establish baseline levels from which fluctuations in these lipids could be compared. The patients were then placed upon a regimen of the above discussed tablets, totaling approximately 1500 mg of nicotinic acid, once per day before going to bed. After eight weeks of this regimen, the patients were again tested for lipid profiles. The results of tests conducted at eight weeks, showing the changes in the lipid profiles as a percentage change from the baseline, are reported in the table hereinbelow. Positive numbers reflect percentage increases and negative numbers reflect percentage decreases in this table.
TABLE II
Patient Study Lipid Profile Data Pt. No. Total-C LDL-C Apo 1=3 Tnes HDL-C I II)L.-C Lp(a) GROtIP A
1 -8.2 -12.0 NA -17.3 22.0 NA NA
2 -5.9 -27.0 NA -28.7 65.0 NA NA
3 -15.1 -13.0 NA -22.0 -9.1 NA NA
4 -3.3 -10 O NA 61.6 3.8 NA NA
5 -16.5 -17.7 NA -28.8 11.1 NA NA
6 -12.4 -25.9 NA -42.0 51.6 NA NA
7 -24.2 -31.4 NA -39.4 12.5 NA NA
8 -6.7 -7.4 NA -42.4 18.8 NA NA
9 4.5 1.1 NA 7.2 9.2 NA NA
10 2.8 -0.2 NA -2.7 22.9 NA NA
Niaspan Tablet Formulations Niaspang Product 375mg Tablets 500mg Tablets .750mg Tablets 1000mg Tablets Fonnulation. % Tablets Niacin 64.4 70.5 77.4 83.1 Methocel E l OM 7.4 8.1 8.9 9.5 Premium (intragranular) 2.2 2.4 2.7 2.9 Povidone K90 Methoccl E l OM
25.0 18.0 10.0 3.5 Prcmium (Extragranular) Hvstrcnc 5016 1.0 1.0 1.0 1.0 (Stearic Acid) Table weight, mg 582.5 709.5 968.6 1203.6 =
Niaspan formulations are presented in white caplet shape tablets. Caplet dimensions differ with respect to product strength. The 375mg and 500mg Niaspan tablets are compressed with tooling measuring approximately 0.687" in length x 0.281" by width. The length and width of the 750mg and 1000mg tooling measures approximately Ø750" x 0.320".
Target tablet weight and hardness dictate thickness across the four Niaspan products. The production of the Niaspan tablets will now be described generally as set forth below.
Niaspan Granulation Process Flow Chart Raw Materials Process Flow Equipment Niacin Granulate High shear granulator Povidone K90 (Littleford FM 130) Methocel E l OM
(Intragranular) Purfied Water Dry Fluid bed drier (Glatt fluid bed drier) Parcel size reduction Mill (Kemutec Betagrind) Niaspan@ Granulation Process Description Niaspan granulation raw materials are dispensed and granulated in a high shear granulator. The wet granules are sieved into a fluid bed drier and are dried.
When the drying process is complete, the granules are milled. Milling ensures uniform particle size distribution throughout the Niaspan granulation.
Niaspan Tablet Process Flow Chart Raw Materials Process Flow Eguioment NiaspanQ Tablet 13lend Mcthoccl 13lend Milled Niaspan(P.) granules Blcnder E l OM with (Patterson-Kelley (Extragranular) extragranular Methocel E l OM and V-Blender) Hystrene ] lystrenc 5016 5016 (Stearic acid) Niaspang T'able Manufacture Compress NiaspanO Tablet Blend Rotary tablet press NiasRan Tablet Process Description A Niaspan tablet blend is manufactured by blending the Niaspan granulation, extragranular Methocel EIOM and Hystrene 5016. The quantities of each Niaspan tablet blend I I I
component will depend on the particular Niaspan dose being manufactured (refer to Table IB).
A Niaspan tablet blend is compressed to form Niaspan tablets. Niaspan tablet physical properties will vary depending on the particular Niaspan dose being manufactured.
Production of Niaspan tablets will now be discussed in greater detail. The initial stage of manufacturing is the same for all four tablet strengths of Niaspan (375, 500, 750 and l 000mg). One batch of Niaspan granulation is comprised of four individual 40.0kg units of granulation which are processed separately, but under like conditions. The four individual granulations are sampled and tested individually and subsequently released for blending. The base granulation is not strength specific and may be used to manufacture any tablet strength of Niaspan .
The ingredients in the base granulation are set froth in Table IC below:
TABLE IC
Component Function Quantity pcr % per Quantity per kilogram kilogram 160.00 kg granulation (kg) granulation batch (kg) (%) Niacin, tISP Drug Substance F 0.87 F 87.00 139.20 inder F 0.03 3.00 4.80 Povidinc, UPS B
F
Methoccl USP, Controlled 0.10 10.00 16.00 E l OM Premium Release Agent CR Grade 0.00' Purified Water, Granulation 0.00' 48 USP' Rcagcnt Total 160 "Purified Water, USP is used as granulation reagent and does not appear in the finished granulation.
Raw materials are quantatively dispensed into appropriately labeled double polyethylene-lined containers using calibrated scales. Purified Water, USP is dispensed into an appropriate vessel from which it is later pumped during the wet-massing operation.
A Littleford FM130 granulator is charged with approximately one half of the Niacin, USP
required for the process unit (-17.4 kg) followed by about 4.00kg of Methocel, USP EIOM
Premium CR Grade; about 1.20kg of Povidine, USP; and the balance of the Niacin, SP
(-17.40kg). The powder bed is dry mixed in the Littleford FM130 granulator, with choppers on, for approximately 1 minute. At the completion of the 1-minute pre-mix cycle, about 12.0 0.05kg SUBSTITUTE SHEET (RULE 26) ,. , of Purified Water, USP are sprayed onto the powder bed at a rate of about 2.40 0.24kg/minute.
Immediately following the addition of the Purified Water, USP, the unit is granulated for about minutes.
The granulated unit is discharged into double polyethylene-lined containers and then 5 manually loaded into a Glatt bowl while being passed through a #4 mesh screen. The Glatt bowl is loaded into a Glatt TFO-60 fluid-bed drier with an inlet air temperature setting of about 70 Ct5 C. The unit is dried until a moisture level of < 1.0% is obtained as determined using a Computrac Moisture Analyzer, model MA5A. The dried granulation is discharged into appropriately labeled, double polyethylene-lined drums and reconciled.
The dried and reconciled granulation is passed through a Kemutec BetaGrind mill equipped with a 1.5mm screen and running at approximately 1500 RPM. The milled granulation is collected into appropriately labeled, double polyethylene-lined drums and reconciled. The milled granulation is sampled and tested by Quality Control and released prior to further processing.
The released granulation units are charged to a Patterson-Kelley 20 ft; V-blender after which they are blended together for about 10 1 minutes and then discharged to appropriately labeled, double polyethylene-lined containers.
As stated above, Niaspan tablets are formulated from a common granulation which is blended with appropriate quantities of Methocel, USP E l OM Premium CR Grade and Stearic Acid, NF to achieve the final dosage forrnulation. Tables IA and IB describe the formulation for each Niaspan tablet strength, 3 75mg, 500mg, 750mg and 1000mg, respectively.
Two study groups consisting of eleven and fourteen patients each were formed.
Blood samples were taken from the patients, and tested for total cholesterol, LDL
cholesterol, triglycerides and HDL cholesterol to establish baseline levels from which fluctuations in these lipids could be compared. The patients were then placed upon a regimen of the above discussed tablets, totaling approximately 1500 mg of nicotinic acid, once per day before going to bed. After eight weeks of this regimen, the patients were again tested for lipid profiles. The results of tests conducted at eight weeks, showing the changes in the lipid profiles as a percentage change from the baseline, are reported in the table hereinbelow. Positive numbers reflect percentage increases and negative numbers reflect percentage decreases in this table.
TABLE II
Patient Study Lipid Profile Data Pt. No. Total-C LDL-C Apo 1=3 Tnes HDL-C I II)L.-C Lp(a) GROtIP A
1 -8.2 -12.0 NA -17.3 22.0 NA NA
2 -5.9 -27.0 NA -28.7 65.0 NA NA
3 -15.1 -13.0 NA -22.0 -9.1 NA NA
4 -3.3 -10 O NA 61.6 3.8 NA NA
5 -16.5 -17.7 NA -28.8 11.1 NA NA
6 -12.4 -25.9 NA -42.0 51.6 NA NA
7 -24.2 -31.4 NA -39.4 12.5 NA NA
8 -6.7 -7.4 NA -42.4 18.8 NA NA
9 4.5 1.1 NA 7.2 9.2 NA NA
10 2.8 -0.2 NA -2.7 22.9 NA NA
11 -13.0 -9.4 NA -54.0 44.3 NA NA
Mean -8.9 -13.9 NA -18.9 23.0 NA NA
p-Valuc 0.0004-8.9 0.0001- 0.0371 0.0068 13.9 GROUP B
1 -19.2 -27.1 -24.4 -33.4 20.0 22.3 -81.9 2 -32.2 -35.7 -28.0 -60.4 4.3 3.2 -25.3 3 -21.4 -33.6 -35.6 -33.4 30.4 38.6 -17.4 4 -19.9 -24.6 -15.1 -20.8 9.6 16.1 -27.0 5 -3.3 -2.1 -29.4 -41.1 5.8 2.4 -22.4 7 23.1 -32.6 -42.6 -58.6 49.2 68.9 -14.3 8 24.8 34.0 -28.4 5.5 6.5 -6.8 NA
9 10.1 12.0 -16.8 -11.6 20.7 -12.3 40.6 10 -2.9 -7.7 -28.0 -59.0 53.1 70.5 -41.2 11 -10.5 -18.8 -25.3 -53.4 31.8 39.7 NA
Mean -8.9 -13.9 NA -18.9 23.0 NA NA
p-Valuc 0.0004-8.9 0.0001- 0.0371 0.0068 13.9 GROUP B
1 -19.2 -27.1 -24.4 -33.4 20.0 22.3 -81.9 2 -32.2 -35.7 -28.0 -60.4 4.3 3.2 -25.3 3 -21.4 -33.6 -35.6 -33.4 30.4 38.6 -17.4 4 -19.9 -24.6 -15.1 -20.8 9.6 16.1 -27.0 5 -3.3 -2.1 -29.4 -41.1 5.8 2.4 -22.4 7 23.1 -32.6 -42.6 -58.6 49.2 68.9 -14.3 8 24.8 34.0 -28.4 5.5 6.5 -6.8 NA
9 10.1 12.0 -16.8 -11.6 20.7 -12.3 40.6 10 -2.9 -7.7 -28.0 -59.0 53.1 70.5 -41.2 11 -10.5 -18.8 -25.3 -53.4 31.8 39.7 NA
12 -20.0 -30.8 -30.4 11.7 21.1 25.0 -28.4
13 17.4 16.8 -17.5 -17.5 51.3 51.9 38.5 1 t 7 TABLE II (Continued) Patient Study Lipid Profile Data Pt. No. Total-C LDL-C Apo B Trias HDL-C I II)L.-C ,aa
14 -9.4 -16.6 -32.0 -46.9 52.3 67.6 17.6 MEAN -8.7 -12.8 -32.2 -27.2 25.3 30.1 -17.9 p-Value 0.0002 <0.0001 0.0001 <0.001 <0.0001 0.0002 <0.0188 Combined -8.7 -13.3 Gp B -26.1 25.3 (ip B Gp 13 p-Valuc: 0.0002 <0.0001 only <.0001 <0.0001 only onlNThe data reported in Table II shows that the LDL levels in the Group A patients had a mean decrease of -13.9% and triglyceride decrease of -18.9% I-IDL cholesterol levels, the beneficial cholesterol, were raised by 23.0% in this Group. Similar results were obtained with the Group B patients. These studies demonstrate that dosing the sustained release formulation during the evening hours or at night provides reductions in LDL cholesterol levels equal to immediate release niacin on a milligam per milligram basis, but superior reductions in triglyceride reduction when compared to sustained release formulations dosed during daytime hours on a milligram per milligram basis. Additionally, the increases in HDL cholesterol obtained from dosing the sustained release formulation during the evening or at night were +23.0% for one group and +25.3% for the other group. Dosing during the evening therefore provides reduction in LDL
cholesterol plus significant decreases in triglycerides and increases in HDL
cholesterol with once-a-day dosing.
Groups A and B were also tested for liver enzymes (AST, ALT and Alkaline Phosphatase), uric acid and fasting glucose levels at the start of the study described hereinabove (to form a baseline) and at two, four and eight week intervals. The results of these tests are listed in TABLES III-VII hereinbelow.
i i TABLE III
THE EFFECT OF NIASPAN THERAPY ON AST (SGOT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range GROUP A
GROUP B
6 PATIt:N"I' WITI-II)RI?W DUE TO FLUSHING
f l 1 TABLE III (Continued) THE EFFECT OF NIASPANO THERAPY ON AST (SGOT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Bascline 2 Wks. 4 Wks. 8 Wks. Reference Range Combined Mean 19.8 204 20,8 21.1 Change From +3.0% +5.1% +6.6%
Haselinc Level of SiFniticancc: p=0.4141 TABLE IV
THE EFFECT OF NIASPANO THERAPY ON ALT (SGPT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range GROUP A
TABLE IV (Continued) THE EFFECT OF NIASPANO THERAPY ON ALT (SGPT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan
cholesterol plus significant decreases in triglycerides and increases in HDL
cholesterol with once-a-day dosing.
Groups A and B were also tested for liver enzymes (AST, ALT and Alkaline Phosphatase), uric acid and fasting glucose levels at the start of the study described hereinabove (to form a baseline) and at two, four and eight week intervals. The results of these tests are listed in TABLES III-VII hereinbelow.
i i TABLE III
THE EFFECT OF NIASPAN THERAPY ON AST (SGOT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range GROUP A
GROUP B
6 PATIt:N"I' WITI-II)RI?W DUE TO FLUSHING
f l 1 TABLE III (Continued) THE EFFECT OF NIASPANO THERAPY ON AST (SGOT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Bascline 2 Wks. 4 Wks. 8 Wks. Reference Range Combined Mean 19.8 204 20,8 21.1 Change From +3.0% +5.1% +6.6%
Haselinc Level of SiFniticancc: p=0.4141 TABLE IV
THE EFFECT OF NIASPANO THERAPY ON ALT (SGPT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range GROUP A
TABLE IV (Continued) THE EFFECT OF NIASPANO THERAPY ON ALT (SGPT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan
15 Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range GROUP B
Combined 17.7 17.5 19.3 18.2 Mean Change -1.1% 9.0% +2.8%
From Baseline Level of Significance: p=0.3424 r ~ ~.
TABLE V
THE EFFECT OF NIASPAN THERAPY
ON ALKALINE PHOSPHATASE LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks 8 Wks Reference Range GROUP A
GROUP B
TABLE V (Continued) THE EFFECT OF NIASPAN THERAPY
ON ALKALINE PHOSPHATASE LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks 8 Wks Reference Range Combined 66.5 61.5 63.3 65.8 Mean Change -6.1% -3.4% +0.005%
From 10 Baseline Level of Significance: p=0.0236 r r r TABLE VI
THE EFFECT OF NIASPAN THERAPY ON URIC ACID LEVELS (mg/dL) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks= 8 Wks. Reference Range GROUP A
1 5.2 5.0 4.8 4.3 4.0-8.5 2 4.0 4.6 4.5 6.2 2.5-7.5 3 6.3 7.0 6.5 6.2 4.0-8.5 4 3.1 4.6 4.2 3.8 2.5-7.5 5 3.4 NA 3.3 4.2 2.5-7.5 6 6.6 5.5 5.6 4.7 4.0-8.5 7 3.8 4.5 4.3 4.9 2.5-7.5 8 4.4 3.8 5.1 4.5 2.5-7.5 9 3.9 4.5 4.6 3.5 2.5-7.5 10 2.6 2.9 2.8 2.7 2.5-7.5 11 4.7 5.5 5.2 5.3 2.5-7.5 GROUP B
1 3.7 4.2 4.7 3.5 2.5-7.5 2 2.8 3.5 3.6 2.3 4.0-8.5 3 4.2 5.3 5.5 5.3 2.5-7.5 4 4.7 3.9 5.1 3.6 4.0-8.5 5 3.7 4.1 4.1 3.8 2.5-7.5 7 5.8 6.6 6.6 6.8 2.5-7.5 8 4.7 4.3 5.4 5.6 2.5-7.5 9 3.7 4.6 5.1 3.8 2.5-7.5 TABLE VI (Continued) THE EFFECT OF NIASPAN THERAPY ON URIC ACID LEVELS (mg/dL) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range 4.2 5.0 4.4 8.5 2.5-7.5 11 1.9 3.0 2.8 5.0 2.5-7.5 12 5.6 5.4 6.2 5.6 4.0-8.5 13 4.2 4.6 4.6 5.3 2.5-7.5 5 14 5.5 5.4 6.1 5.3 2.5-7.5 Combined 4.54 4.82 4.92 4.86 *p=0.3450 Mean Change +6.2% +8.4% +7.0%
From 10 Baseline *Level of Significance: p=0.3450 ~ r. i TABLE VII
THE EFFECT OF NIASPANO THERAPY
ON FASTING GLUCOSE LEVELS (mg/dL) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks. 8 Wks Reference Range GROUP A
GROUP B
TABLE VII (Continued) THE EFFECT OF NIASPAN THERAPY
ON FASTING GLUCOSE LEVELS (mg/dL) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks. 8 Wks Reference Range Combined 98,4 105.8 101.6 102.3 Mean Change From +7.5% +3.3% +4.01%
Baseline Level of Significance: p=0-0021 In order to provide a comparison between the state of the art prior to the present invention, and in order to quantify the magnitude of the improvement that the invention provides over the prior art, another study was conducted. This study included 240 patients dosed with the sustained release formulation according to the present invention as described hereinabove. Compared to this group was the group of patients studied by McKenney et al, as reported hereinabove. The results of this study are reported in TABLE VIII
hereinbelow.
TABLE VIII ~
A Comparison of Changes in Liver Function Tests DOSE
S
McKenney Srb Niacina AST 23.8 27.9 40.4 36.6 56.5 na 97 0 >
% ~- 117 170 154 237 na 408 Invention Dosage' AST 24.3 na 23.7 17.5 26.6 27.6 27.8 % ~-- na 98 113 109 114 114 J F
McKenney SR
Niacin ALT 25.6 29.5 36.3 39.0 59. I NA 100 0 % ~- 115 142 152 231 NA 391 ~-~
Invention Dosage [
ALT F 21.4 na 18.7 22.6 21.3 1 22.4 121 20 % ~- na 87 106 100 105 102 McKenney SR
Niacin ALK 95 95 106 105 136 na 135 TABLE Vlil (Continued) A Comparison of Changes in Liver Function Tests DOSE
% F100 112 lll 143 na 142 Invention Dosage FI-ALK 74.7 na 73.9 761 73 4 767 780 % ~-- na 99 102 98 103 101 McKenney SR r Niacin _ i Drop ~ 0 1 2 4 na 5 12 ~ o n 23 F F -- 0 4 F 9 17 na 1 22 52 Invention Dosage F ~- ~ r I I
Drop F -- r 0 0 0 0 ~- 0 n ~ -- 26 67 97 35 15 1240 % ~ -- f 0 0 0 0 fo 0 10 year -- I -- 15 I 46 77 31 I 5 184 I a 58 69 79 89 100 77 ~0 year -~
a Dosed twice-per-day as described in "A Comparison of the Efficacy and Toxic Effects of Sustained - vs Immediate - Release Niacin in Hypercholesterolemic Patients" by McKenney et al Journal of the American Medical Association, March 2, 1994; Vol. 271, No. 9, pages 6 7 2-677.
b SR is "sustained release"
' Dosed once-per-day at night The results of the comparison of the studies reported in Table VIII show that the control group (the McKenney group) had 12 of 23, or 52 percent of the patients therein drop out. of the test because of an increase in their respective liver function tests. The patients withdrew- at the direction of the investigator. In comparison, a group of 240 patients treated according to the present invention had zero patients drop out, based upon the same criteria for withdrawa.l. The test results reported above indicate that this sustained release dosage form caused no elevation in liver function tests (i_e., no liver damage), no elevations in uric acid and only a small, 7.59:b increase in fasting glucose levels which in fact decreased during continued therapy.
Thus it should be evident that the compositions and method of the present invention are highly effective in controlling hyperlipidemia in hyperlipidemics, by reducing the levels ef LDL
cholesterol, triglyceride and Lp(a) while increasing HDL cholesterol levels.
The present invention is also demonstrated not to cause elevations in liver function tests, uric acid or glucose levels for the hyperlipidemics.
Based upon the foregoing disclosure, it should now be apparent that the use of the compositions and methods described herein will carry out the objects set forth hereinabove_ It is, therefore, to be understood that any variations in sustained release formulation evident fall within the scope of the claimed invention and thus, the selection of specific component elements can be determined without departing from the spirit of the invention herein disclosed and described. In particular, sustained release excipients, binders and processing aids accorcling to the present invention are not necessarily limited to those exemplified hereinabove. Thus, the scope of the invention shall include all modifications and variations that may fall within the scope of the attached claims.
Combined 17.7 17.5 19.3 18.2 Mean Change -1.1% 9.0% +2.8%
From Baseline Level of Significance: p=0.3424 r ~ ~.
TABLE V
THE EFFECT OF NIASPAN THERAPY
ON ALKALINE PHOSPHATASE LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks 8 Wks Reference Range GROUP A
GROUP B
TABLE V (Continued) THE EFFECT OF NIASPAN THERAPY
ON ALKALINE PHOSPHATASE LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks 8 Wks Reference Range Combined 66.5 61.5 63.3 65.8 Mean Change -6.1% -3.4% +0.005%
From 10 Baseline Level of Significance: p=0.0236 r r r TABLE VI
THE EFFECT OF NIASPAN THERAPY ON URIC ACID LEVELS (mg/dL) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks= 8 Wks. Reference Range GROUP A
1 5.2 5.0 4.8 4.3 4.0-8.5 2 4.0 4.6 4.5 6.2 2.5-7.5 3 6.3 7.0 6.5 6.2 4.0-8.5 4 3.1 4.6 4.2 3.8 2.5-7.5 5 3.4 NA 3.3 4.2 2.5-7.5 6 6.6 5.5 5.6 4.7 4.0-8.5 7 3.8 4.5 4.3 4.9 2.5-7.5 8 4.4 3.8 5.1 4.5 2.5-7.5 9 3.9 4.5 4.6 3.5 2.5-7.5 10 2.6 2.9 2.8 2.7 2.5-7.5 11 4.7 5.5 5.2 5.3 2.5-7.5 GROUP B
1 3.7 4.2 4.7 3.5 2.5-7.5 2 2.8 3.5 3.6 2.3 4.0-8.5 3 4.2 5.3 5.5 5.3 2.5-7.5 4 4.7 3.9 5.1 3.6 4.0-8.5 5 3.7 4.1 4.1 3.8 2.5-7.5 7 5.8 6.6 6.6 6.8 2.5-7.5 8 4.7 4.3 5.4 5.6 2.5-7.5 9 3.7 4.6 5.1 3.8 2.5-7.5 TABLE VI (Continued) THE EFFECT OF NIASPAN THERAPY ON URIC ACID LEVELS (mg/dL) (1500 mgs dosed once-a-day at night) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range 4.2 5.0 4.4 8.5 2.5-7.5 11 1.9 3.0 2.8 5.0 2.5-7.5 12 5.6 5.4 6.2 5.6 4.0-8.5 13 4.2 4.6 4.6 5.3 2.5-7.5 5 14 5.5 5.4 6.1 5.3 2.5-7.5 Combined 4.54 4.82 4.92 4.86 *p=0.3450 Mean Change +6.2% +8.4% +7.0%
From 10 Baseline *Level of Significance: p=0.3450 ~ r. i TABLE VII
THE EFFECT OF NIASPANO THERAPY
ON FASTING GLUCOSE LEVELS (mg/dL) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks. 8 Wks Reference Range GROUP A
GROUP B
TABLE VII (Continued) THE EFFECT OF NIASPAN THERAPY
ON FASTING GLUCOSE LEVELS (mg/dL) (n = 28) Weeks of Therapy With Niaspan Pt# Baseline 2 Wks 4 Wks. 8 Wks Reference Range Combined 98,4 105.8 101.6 102.3 Mean Change From +7.5% +3.3% +4.01%
Baseline Level of Significance: p=0-0021 In order to provide a comparison between the state of the art prior to the present invention, and in order to quantify the magnitude of the improvement that the invention provides over the prior art, another study was conducted. This study included 240 patients dosed with the sustained release formulation according to the present invention as described hereinabove. Compared to this group was the group of patients studied by McKenney et al, as reported hereinabove. The results of this study are reported in TABLE VIII
hereinbelow.
TABLE VIII ~
A Comparison of Changes in Liver Function Tests DOSE
S
McKenney Srb Niacina AST 23.8 27.9 40.4 36.6 56.5 na 97 0 >
% ~- 117 170 154 237 na 408 Invention Dosage' AST 24.3 na 23.7 17.5 26.6 27.6 27.8 % ~-- na 98 113 109 114 114 J F
McKenney SR
Niacin ALT 25.6 29.5 36.3 39.0 59. I NA 100 0 % ~- 115 142 152 231 NA 391 ~-~
Invention Dosage [
ALT F 21.4 na 18.7 22.6 21.3 1 22.4 121 20 % ~- na 87 106 100 105 102 McKenney SR
Niacin ALK 95 95 106 105 136 na 135 TABLE Vlil (Continued) A Comparison of Changes in Liver Function Tests DOSE
% F100 112 lll 143 na 142 Invention Dosage FI-ALK 74.7 na 73.9 761 73 4 767 780 % ~-- na 99 102 98 103 101 McKenney SR r Niacin _ i Drop ~ 0 1 2 4 na 5 12 ~ o n 23 F F -- 0 4 F 9 17 na 1 22 52 Invention Dosage F ~- ~ r I I
Drop F -- r 0 0 0 0 ~- 0 n ~ -- 26 67 97 35 15 1240 % ~ -- f 0 0 0 0 fo 0 10 year -- I -- 15 I 46 77 31 I 5 184 I a 58 69 79 89 100 77 ~0 year -~
a Dosed twice-per-day as described in "A Comparison of the Efficacy and Toxic Effects of Sustained - vs Immediate - Release Niacin in Hypercholesterolemic Patients" by McKenney et al Journal of the American Medical Association, March 2, 1994; Vol. 271, No. 9, pages 6 7 2-677.
b SR is "sustained release"
' Dosed once-per-day at night The results of the comparison of the studies reported in Table VIII show that the control group (the McKenney group) had 12 of 23, or 52 percent of the patients therein drop out. of the test because of an increase in their respective liver function tests. The patients withdrew- at the direction of the investigator. In comparison, a group of 240 patients treated according to the present invention had zero patients drop out, based upon the same criteria for withdrawa.l. The test results reported above indicate that this sustained release dosage form caused no elevation in liver function tests (i_e., no liver damage), no elevations in uric acid and only a small, 7.59:b increase in fasting glucose levels which in fact decreased during continued therapy.
Thus it should be evident that the compositions and method of the present invention are highly effective in controlling hyperlipidemia in hyperlipidemics, by reducing the levels ef LDL
cholesterol, triglyceride and Lp(a) while increasing HDL cholesterol levels.
The present invention is also demonstrated not to cause elevations in liver function tests, uric acid or glucose levels for the hyperlipidemics.
Based upon the foregoing disclosure, it should now be apparent that the use of the compositions and methods described herein will carry out the objects set forth hereinabove_ It is, therefore, to be understood that any variations in sustained release formulation evident fall within the scope of the claimed invention and thus, the selection of specific component elements can be determined without departing from the spirit of the invention herein disclosed and described. In particular, sustained release excipients, binders and processing aids accorcling to the present invention are not necessarily limited to those exemplified hereinabove. Thus, the scope of the invention shall include all modifications and variations that may fall within the scope of the attached claims.
Claims (62)
1. An oral dosage sustained release pharmaceutical formulation for use once per day during the evening or at night, or before bedtime, as a single dose, for daily treatment of hyperlipidemia in a patient without inducing treatment-limiting liver damage, said formulation comprising a blend of:
(a) an effective antihyperlipidemic amount of nicotinic acid in milled agglomerates of the nicotinic acid, a portion of the total amount of swelling agent, and a granulation binder, the milled agglomerates being of a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant;
wherein said total amount of swelling agent functions as a controlled release agent, to form an oral sustained release solid dosage form, and wherein the oral sustained release solid dosage form does not contain an internal hydrophobic component, said single daily oral dose causing no treatment-limiting damage to the liver of the patient.
(a) an effective antihyperlipidemic amount of nicotinic acid in milled agglomerates of the nicotinic acid, a portion of the total amount of swelling agent, and a granulation binder, the milled agglomerates being of a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant;
wherein said total amount of swelling agent functions as a controlled release agent, to form an oral sustained release solid dosage form, and wherein the oral sustained release solid dosage form does not contain an internal hydrophobic component, said single daily oral dose causing no treatment-limiting damage to the liver of the patient.
2. A formulation as set forth in claim 1, wherein the oral dose is from about 250 mg to about 3000 mg of nicotinic acid.
3. A formulation as set forth in claim 1, wherein the oral dose is about 1000 mg of nicotinic acid.
4. A formulation as set forth in claim 1, wherein the oral sustained release solid dosage form contains nicotinic acid in an amount selected from the group consisting of about 375 mg, about 500 mg and about 750 mg.
5. A formulation as set forth in claim 1, 2, 3 or 4, wherein the oral sustained release solid dosage form is an oral sustained release tablet.
6. A formulation as set forth in claim 1, 2, 3, 4 or 5, wherein said single daily dose is effective to elevate HDL cholesterol in the patient.
7. A formulation as set forth in claim 1, 2, 3, 4 or 5, wherein said single daily dose is effective to induce at least some decrease in levels of total cholesterol, LDL cholesterol, triglycerides and Lp(a) in the patient.
8. A formulation as set forth in any one of claims 1 to 7, wherein said single daily dose causes no treatment-limiting increase in uric acid in the patient.
9. A formulation as set forth in any one of claims 1 to 8, wherein said single daily dose treatment causes no treatment-limiting increase in free fasting glucose in the patient.
10. A formulation as set forth in any one of claims 1 to 9, wherein said single daily dose treatment causes no anomalies in a liver function test in the patient to an extent which would require daily treatment to be discontinued, and wherein the liver function test is selected from the group consisting of an AST, ALT and alkaline phosphatase liver function test.
11. A formulation, as set forth in any one of claims 1 to 10, wherein said oral sustained release formulation is in the form of a tablet which contains:
(a) about 30% to about 90% parts by weight nicotinic acid, and (b) about 5% to about 50% parts by weight hydroxypropyl methylcellulose as said swelling agent.
(a) about 30% to about 90% parts by weight nicotinic acid, and (b) about 5% to about 50% parts by weight hydroxypropyl methylcellulose as said swelling agent.
12. A formulation for treating hyperlipidemia in a patient with an effective amount of nicotinic acid once per day during the evening or at night, or before bedtime, comprising a blend of:
(a) milled agglomerates of nicotinic acid, a portion of a total amount of swelling agent, and a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant, wherein the swelling agent in said total amount functions as a controlled release agent, to form an oral sustained release solid dosage form, and wherein said oral sustained release solid dosage form does not contain an internal hydrophobic component.
(a) milled agglomerates of nicotinic acid, a portion of a total amount of swelling agent, and a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant, wherein the swelling agent in said total amount functions as a controlled release agent, to form an oral sustained release solid dosage form, and wherein said oral sustained release solid dosage form does not contain an internal hydrophobic component.
13. A formulation as set forth in claim 12, wherein said oral sustained release solid dosage form comprises from about 250 mg to about 3000 mg of nicotinic acid.
14. A formulation as set forth in claim 12, wherein said oral sustained release solid dosage form comprises about 1000 mg of nicotinic acid.
15. A formulation as set forth in claim 12, wherein said oral sustained release ~olid dosage form contains nicotinic acid in an amount selected from, the group consisting of about 375 mg, about 500 mg and about 750 mg.
16. A formulation as set forth in claim 12, 13 or 15, wherein said oral sustained I release solid dosage form is an oral sustained release tablet.
17. A formulation as set forth in claim 16, wherein said oral sustained release, tablet contains {~) about 375 rog nicotinic acid, (~) about 189 mg hydroxypropyl methylcellulose as said total amount of the swelling agent, (~) about 13 mg polyvinyl pyrrolidone as said granulation binder, and (~) about 6 mg of stearic acid as said lubricant.
18. 1- formulation as set forth in claim 16, wherein said oral sustained release tablet contains (~) about 500 mg nicotinic acid, (~) about 203 mg hydroxypropyl methylcellulose as said total amount of the swelling agent, (~) about 17 mg polyvinyl pyrrolidone as said granulation binder, and {~) about 7 mg stearic acid as said lubricant.
19. A formulation as set forth in claim 16, wherein said oral sustained release tablet contains (~) about 750 mg nicotinic acid, (~) about 205 mg hydroxypropyl methylcellulose as said total amount of the swelling agent, (~) about 26 mg polyvinyl pyrrolidone as said granulation binder, and (~) about 10 mg stearic acid as said lubricant.
20. A formulation as set forth in claim 16, wherein said oral sustained release tablet contains (~) about 30% to about 90% by weight nicotinic acid, (~)about 5% to about 50% by weight hydroxypropyl methylcellulose as said total amount of the swelling agent, (c) about 1% to about 5% by weight polyvinyl pyrrolidone as said granulation. binder, and (d) about 0.5% to about 2% by weight stearic acid as said lubricant.
21. A formulation as set forth in claim 16, wherein said oral sustained release tablet contains (a) about 30% to about 90% parts by weight nicotinic acid, and (b) about 5% to about 50% parts by weight hydroxypropyl methylcellulose as said total amount of the swelling agent.
22. Use of a formulation as set forth in any one of claims 1 to 21 for treating hyperlipidemia in a patient without inducing treatment-limiting (i) hepatotoxicity and (ii) abnormalities in uric acid levels or glucose levels or both to an extent which would require the use of said formulation to be discontinued.
23. A sustained release formulation of nicotinic acid for oral administration to a patient once per day during the evening or at night, or before bedtime, for providing an effective antihyperlipidemic amount of nicotinic acid to the patient to induce at least some lowering of total cholesterol, LDL
cholesterol, triglycerides and Lp(a) and at least some increase in HDL cholesterol in the patient's blood stream, without causing abnormalities in uric acid levels or glucose levels or both to an extent which would require the use of said sustained release formulation by the patient to be discontinued, said sustained release formulation comprising a blend of:
(a) milled agglomerates of:
(i) an effective antihyperlipidemic amount of nicotinic acid, (ii) an excipient to provide sustained release of the nicotinic acid, said excipient comprising a portion of a total amount of a swelling agent, and (iii) a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent, and (c) an external lubricant, said total amount of swelling agent functioning as a controlled release agent.
cholesterol, triglycerides and Lp(a) and at least some increase in HDL cholesterol in the patient's blood stream, without causing abnormalities in uric acid levels or glucose levels or both to an extent which would require the use of said sustained release formulation by the patient to be discontinued, said sustained release formulation comprising a blend of:
(a) milled agglomerates of:
(i) an effective antihyperlipidemic amount of nicotinic acid, (ii) an excipient to provide sustained release of the nicotinic acid, said excipient comprising a portion of a total amount of a swelling agent, and (iii) a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent, and (c) an external lubricant, said total amount of swelling agent functioning as a controlled release agent.
24. A sustained release formulation of claim 23, wherein the excipient further comprises a processing aid.
25. A sustained release formulation of claim 24, wherein the swelling agent is selected from group consisting of a polymer, a wax, a natural material selected from the group consisting of gums and gelatins, and mixtures thereof.
26. A sustained release formulation of claim 25, wherein the polymer is selected from the group consisting of hydroxypropyl methylcellulose, sodium carboxymethylcellulose and ethylcellulose.
27. A sustained release formulation of claim 25, wherein the wax is bees wax.
28. A sustained release formulation of claim 25, wherein the natural material is a gum.
29. A. sustained release formulation of claim 24, wherein the granulation binder is povidone.
30. A sustained release formulation of claim 24, wherein the.processing aid is a lubricant.
31. A sustained release formulation of claim 30, wherein the lubricant is stearic acid.
32. A sustained release formulation of claim 26, wherein the polymer is hydroxypropyl methylcellulose in an amount ranging from about 5% to about 50% parts by weight per 100 parts by weight of the sustained release formulation.
33. A sustained release formulation of claim 24, wherein the granulation binder is in an amount ranging from about 1% to about 5% parts by weight per 100 parts by weight of the sustained release formulation.
34. A sustained release formulation of claim 24, wherein the processing aid is in an amount ranging from about 0.5% to about 2% parts by weight per 100 parts by weight of the sustained release formulation.
33. A sustained release formulation of claim 23, wherein the sustained release formulation consists essentially of nicotinic acid, hydroxypropyl methylcellulose, povidone and stearic acid.
36. A sustained release formulation of claim 23, wherein the sustained release formulation consists essentially of nicotinic acid 375.0 mg, hydroxypropyl methylcellulose 188.7 mg, povidone 12.9 mg, and stearic acid 5.8 mg.
37. A sustained release formulation of claim 23, wherein the sustained release formulation consists essentially of nicotinic acid 500.0 mg, hydroxypropyl methylcellulose 203.0 mg, povidone 17.2 mg, and stearic acid 7.3 mg.
38. A sustained release formulation of claim 23, wherein the sustained release formulation consists essentially of nicotinic acid 750.0 mg, hydroxypropyl methylcellulose 204.7 mg, povidone 25.9 mg, and stearic acid 9.9 mg.
39. Use of a sustained release formulation of any one of claims 23 to 38 for daily treating hyperlipidemia in a patient without inducing treatment-limiting elevations in uric acid levels or glucose levels or both in the patient, said formulation being in a form for orally dosing the patient with an effective antihyperlipidemic a,mount of nicotinic acid once per day during the evening or at night, or before bedtime, as a single dose, wherein said single dose treatment induces at least some (i) decrease in levels of total cholesterol, LDL
cholesterol, triglycerides and Lp(a) and (ii) some elevation in RDL
cholesterol in the patient.
cholesterol, triglycerides and Lp(a) and (ii) some elevation in RDL
cholesterol in the patient.
40. Use of a sustained release formulation of any one of claims 23 to 38 for treating hyperlipidemia in a patient without inducing treatment-limiting (i) hepatotoxicity and (ii) abnormalities in uric acid levels or glucose levels or both, said formulation being in a form for orally dosing the patient with an effective antihyperlipidemic amount of nicotinic acid once per day during the evening or at night, or before bedtime, as a single dose, wherein the oral sustained release solid dosage form is effective in reducing a serum lipid without causing treatment-limiting (a) hepatotoxicity and (b) elevations in uric acid levels or glucose levels or both in the patient to a level which would require said treatment to be discontinued by the patient when it is ingested by the patient once per day during the evening or at night as the single dose in accordance with said single dose treatment.
41. Use of a sustained release formulation of any one of claims 23 to 38 for daily treating hyperlipidemia in a patient, said formulation being in a form for orally administering to the patient once per day during the evening or night, or before bedtime, for providing an effective antihyperlipidemic amount of nicotinic acid to the patient during times of peak lipid production or synthesis by the patient to induce at least. some lowering of total cholesterol, LDL
cholesterol, triglycerides and Lp(a) and at least some increase in HDL
cholesterol in the patient's blood stream, without causing abnormalities in liver function tests and uric acid levels or glucose levels to an extent which would require said daily treatment to be discontinued by the patient.
cholesterol, triglycerides and Lp(a) and at least some increase in HDL
cholesterol in the patient's blood stream, without causing abnormalities in liver function tests and uric acid levels or glucose levels to an extent which would require said daily treatment to be discontinued by the patient.
42. A sustained release formulation of nicotinic acid for oral administration to a patient once per day during the evening or night , or before bedtime, or as the patient lies down to go to sleep for providing an effective antihyperlipidemic amount of nicotinic acid to the patient during times of peak lipid production or synthesis by the patient to induce at least some lowering of total cholesterol, LDL cholesterol, triglycerides and Lp(a) and at least some increase in HDL cholesterol in the patient's blood stream, without causing abnormalities in liver function tests and uric acid levels or glucose levels or both to an extent which would require the use of said sustained release formulation by the patient to be discontinued, the sustained release formulation comprising a blend of:
(a) mixed agglomerates of:
(i) an effective antihyperlipidemic amount of nicotinic acid, (ii) an excipient to provide sustained release of the nicotinic acid, said excipient comprising a portion of a total amount of a swelling agent, and (iii) a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant, wherein said total amount of swelling agent functions as a controlled release agent.
(a) mixed agglomerates of:
(i) an effective antihyperlipidemic amount of nicotinic acid, (ii) an excipient to provide sustained release of the nicotinic acid, said excipient comprising a portion of a total amount of a swelling agent, and (iii) a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant, wherein said total amount of swelling agent functions as a controlled release agent.
43. A pharmaceutical formulation for treating hyperlipidermia in a hyperlipidemic comprising an effective antihyperlipidemic amount of a compound which is metabolized to nicotinic acid by the hyperlipidemic to produce (i) a reduction in total and LDL cholesterol, triglycerides and Lp(a), and (ii) an increase in HDL cholesterol, wherein the compound is combined with at least one pharmaceutically acceptable carrier comprising a swelling agent in a total amount which functions as a controlled release agent, to form an oral solid dosage form, and wherein the compound is selected. from the group consisting of d-glucitol hexanicotinate, aluminum nicotinate: and d,l-alpha-tocopheryl nicotinate, said formulation comprising a blend of:
(a) milled agglomerates of said compound, a portion of the total amount of swelling agent, and a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant.
(a) milled agglomerates of said compound, a portion of the total amount of swelling agent, and a granulation binder, the milled agglomerates having a uniform particle size distribution, and (b) the remaining portion of the total amount of swelling agent and an external lubricant.
44. A method of manufacturing a sustained release nicotinic acid solid dosage form, said method comprising:
(a) forming a wet granulation which consists essentially of nicotinic acid, a portion of a total amount of a swelling agent which functions as a controlled release agent, and a granulation binder;
(b) drying the wet granulation to form dry granules;
(c) milling the dry granules to obtain a substantially uniform particle size distribution;
(d) dry blending the milled dry granules, the remaining portion of the total amount of swelling agent, and an external lubricant to form a final dosage blend; and (e) forming the sustained release nicotinic acid solid dosage form from the final dosage blend.
(a) forming a wet granulation which consists essentially of nicotinic acid, a portion of a total amount of a swelling agent which functions as a controlled release agent, and a granulation binder;
(b) drying the wet granulation to form dry granules;
(c) milling the dry granules to obtain a substantially uniform particle size distribution;
(d) dry blending the milled dry granules, the remaining portion of the total amount of swelling agent, and an external lubricant to form a final dosage blend; and (e) forming the sustained release nicotinic acid solid dosage form from the final dosage blend.
45. A method as set forth in claim 44, wherein step (a) comprises:
forming a dry mix which consists essentially of said nicotinic acid, said portion of said total amount of a swelling agent and said granulation binder;
and forming said wet granulation from the dry mix.
forming a dry mix which consists essentially of said nicotinic acid, said portion of said total amount of a swelling agent and said granulation binder;
and forming said wet granulation from the dry mix.
46. A method as set forth in claim 44 or 45, wherein the sustained release nicotinic acid solid dosage form is a sustained release nicotinic acid tablet.
47. A method as set forth in claim 44, 45 or 46, wherein said oral sustained release solid dosage form comprises from about 250 mg to about 3000 mg of nicotinic acid.
48. A method as set forth in claim 46, wherein said oral sustained released tablet contains nicotinic acid in an amount selected from the group consisting of about 375 mg, about 500 mg and about 750 mg.
49. A method as set forth in claim 44, 45, 46, 47 or 48, wherein the swelling agent which functions as the controlled-release agent is selected from the group consisting of a polymer, a wax, a natural material selected from the group consisting of gums and gelatins, and mixtures thereof.
50. A method as set forth in claim 49, wherein the polymer is selected from the group consisting of hydroxypropyl methylcellulose, sodium carboxymethylcellulose and ethylcellulose.
51. A method as set forth in claim 49, wherein the wax is bees wax.
52. A method as set forth in claim 51, wherein the natural material is a gelatin.
53. A method as set forth in any one of claims 44 to 52, wherein the granulation binder is povidone.
54. A method as set forth in any one of claims 44 to 53, wherein the lubricant is stearic acid.
55. A method as set forth in any one of claims 44 to 50, wherein the swelling agent which functions as the controlled-release agent is hydroxypropyl methylcellulose which is in an amount ranging from about 5%
to about 50% parts by weight per 100 parts by weight of the sustained release formulation.
to about 50% parts by weight per 100 parts by weight of the sustained release formulation.
56. A method as set forth in any one of claims 44 to 55, wherein the granulation binder is in an amount ranging from about 1% to about 5% parts by weight per 100 parts by weight of the sustained release nicotinic acid solid dosage.
57. A method as set forth in any one of claims 44 to 56, wherein the external lubricant is in an amount ranging from about 0.5% to about 2% parts by weight per 100 parts by weight of the sustained release nicotinic acid solid dosage.
58. A method as set forth in any one of claims 44 to 48, wherein the sustained release nicotinic acid solid dosage consists essentially of nicotinic acid, hydroxypropyl methylcellulose, povidone and stearic acid.
59. A formulation as set forth in claim 16, wherein said oral sustained release tablet contains:
(a) about 500 mg nicotinic acid, (b) about 185 mg hydroxypropyl methylcellulose as said swelling agent, (c) about 17 mg polyvinyl pyrrolidone as said granulation binder, and (d) about 7 mg of stearic acid as said lubricant.
(a) about 500 mg nicotinic acid, (b) about 185 mg hydroxypropyl methylcellulose as said swelling agent, (c) about 17 mg polyvinyl pyrrolidone as said granulation binder, and (d) about 7 mg of stearic acid as said lubricant.
60. A formulation as set forth in claim 16, wherein said oral sustained release tablet contains:
(a) about 750 mg nicotinic acid, (b) about 183 mg hydroxypropyl methylcellulose as said swelling agent, (c) about 26 mg polyvinyl pyrrolidone as said granulation binder, and (d) about 9.7 mg stearic acid as said lubricant.
(a) about 750 mg nicotinic acid, (b) about 183 mg hydroxypropyl methylcellulose as said swelling agent, (c) about 26 mg polyvinyl pyrrolidone as said granulation binder, and (d) about 9.7 mg stearic acid as said lubricant.
61. A formulation as set forth in claim 12, wherein said oral sustained release dosage form is an oral sustained release tablet which contains:
(a) about 1000 mg nicotinic acid, (b) about 156 mg hydroxypropyl methylcellulose as said swelling agent, (c) about 35 mg polyvinyl pyrrolidone as said granulation binder, and (d) about 12 mg stearic acid as said lubricant.
(a) about 1000 mg nicotinic acid, (b) about 156 mg hydroxypropyl methylcellulose as said swelling agent, (c) about 35 mg polyvinyl pyrrolidone as said granulation binder, and (d) about 12 mg stearic acid as said lubricant.
62. A sustained release formulation of any one of claims 23 to 35, wherein said effective amount of nicotinic acid is 1000 mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002574987A CA2574987A1 (en) | 1997-03-06 | 1998-03-06 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US814,974 | 1997-03-06 | ||
| US08/814,974 US6129930A (en) | 1993-09-20 | 1997-03-06 | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| PCT/US1998/004590 WO1998039002A1 (en) | 1997-03-06 | 1998-03-06 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002574987A Division CA2574987A1 (en) | 1997-03-06 | 1998-03-06 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2283159A1 CA2283159A1 (en) | 1998-09-11 |
| CA2283159C true CA2283159C (en) | 2007-06-19 |
Family
ID=25216509
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002283322A Expired - Lifetime CA2283322C (en) | 1997-03-06 | 1998-03-06 | Starter kit containing nicotinic acid compositions |
| CA002591710A Abandoned CA2591710A1 (en) | 1997-03-06 | 1998-03-06 | Starter kit containing nicotinic acid compositions |
| CA002283159A Expired - Lifetime CA2283159C (en) | 1997-03-06 | 1998-03-06 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002283322A Expired - Lifetime CA2283322C (en) | 1997-03-06 | 1998-03-06 | Starter kit containing nicotinic acid compositions |
| CA002591710A Abandoned CA2591710A1 (en) | 1997-03-06 | 1998-03-06 | Starter kit containing nicotinic acid compositions |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6129930A (en) |
| EP (2) | EP0966284B1 (en) |
| AT (1) | ATE289197T1 (en) |
| AU (2) | AU6348198A (en) |
| BR (2) | BR9815457A (en) |
| CA (3) | CA2283322C (en) |
| DE (1) | DE69829042T2 (en) |
| ES (1) | ES2234100T3 (en) |
| FI (2) | FI119910B (en) |
| NO (2) | NO994275L (en) |
| WO (2) | WO1998039002A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6676967B1 (en) * | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US20060263428A1 (en) * | 1993-09-20 | 2006-11-23 | Eugenio Cefali | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
| US20080045573A1 (en) * | 1993-09-20 | 2008-02-21 | Bova David J | Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia |
| US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| EP2319513A1 (en) * | 1993-09-20 | 2011-05-11 | Abbott Respiratory LLC | Nicotinic acid compositons for treating hyperlipidemia and related methods therefor |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
| CA2298549C (en) * | 1997-07-31 | 2006-01-10 | Kos Pharmaceuticals, Inc. | Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
| US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| AU2003222009A1 (en) * | 2002-03-18 | 2003-10-08 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative |
| PL364348A1 (en) | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| KR100574554B1 (en) * | 2004-05-28 | 2006-04-27 | 한미약품 주식회사 | Sustained release composition for oral administration of niacin |
| AU2006329564A1 (en) | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| US20090069275A1 (en) * | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
| AU2007223787A1 (en) * | 2006-03-08 | 2007-09-13 | Pharmena North America Inc. | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries |
| US8658160B1 (en) | 2006-10-17 | 2014-02-25 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Composition and method for cancer chemoprevention |
| US20080171085A1 (en) * | 2007-01-11 | 2008-07-17 | Natrol, Inc. | Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration |
| WO2008100249A1 (en) * | 2007-02-13 | 2008-08-21 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| WO2009067684A1 (en) * | 2007-11-21 | 2009-05-28 | Capricorn Pharma Inc. | Modified release niacin formulations |
| KR20110011643A (en) * | 2008-06-02 | 2011-02-08 | 닥터 레디스 레보러터리즈 리미티드 | Modified release niacin formulations |
| WO2009149056A2 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Combinations of niacin and an oxicam |
| RU2657797C2 (en) | 2012-06-15 | 2018-06-15 | Конарис Рисерч Инститьют Аг | Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| US10758552B2 (en) | 2013-12-13 | 2020-09-01 | Conaris Research Institute Ag | Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| EP3079675B1 (en) * | 2013-12-13 | 2020-02-12 | CONARIS research institute AG | A pharmaceutical composition containing nicotinic acid and/or nicotinamide for use in beneficially influencing blood lipid levels by modifying the intestinal microbiota |
Family Cites Families (249)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US32581A (en) * | 1861-06-18 | Mortimer kelson | ||
| US29652A (en) * | 1860-08-14 | maltby | ||
| US2510164A (en) * | 1945-04-24 | 1950-06-06 | Us Agriculture | Water-insoluble derivatives of nicotinic acid and process for preparing them |
| US2540979A (en) * | 1948-04-24 | 1951-02-06 | Smith Kline French Lab | Enteric coating |
| US2749274A (en) * | 1952-05-06 | 1956-06-05 | Bristol Lab Inc | Stable aqueous procaine penicillin suspension |
| US2798837A (en) * | 1952-11-20 | 1957-07-09 | Sahyun Melville | Achlorhydria composition |
| US2851453A (en) * | 1954-08-09 | 1958-09-09 | Smith Kline French Lab | Cellulose derivative product, compositions comprising the same and their preparation |
| US2798838A (en) * | 1954-11-10 | 1957-07-09 | Smith Kline French Lab | Method of preparing acetophenetidin tablets |
| US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
| US2857313A (en) * | 1956-03-27 | 1958-10-21 | Ciba Pharm Prod Inc | Self-lubricating granulation |
| US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| DE1228029C2 (en) * | 1964-05-09 | 1973-05-17 | Merck Ag E | Process for the production of tablets by pressing powder mixtures without prior granulation |
| US3930017A (en) * | 1965-10-07 | 1975-12-30 | Horst Kummer | Lowering blood cholesterol and lipid levels |
| US3849554A (en) * | 1965-12-01 | 1974-11-19 | Nasa | Reduction of blood serum cholesterol |
| US3862332A (en) * | 1967-05-11 | 1975-01-21 | Dow Chemical Co | Method of lowering serum cholesterol |
| US3639636A (en) * | 1967-06-01 | 1972-02-01 | Dow Chemical Co | Method of lowering serum cholesterol |
| US3626071A (en) * | 1968-03-08 | 1971-12-07 | Richardson Merrell Inc | Compositions and methods for reducing cholesterol in the blood |
| US3495011A (en) * | 1968-10-28 | 1970-02-10 | Unimed Inc | Reduction of blood level cholesterol |
| US3634584A (en) * | 1969-02-13 | 1972-01-11 | American Home Prod | Sustained action dosage form |
| US3590117A (en) * | 1969-03-24 | 1971-06-29 | Richardson Merrell Inc | Long-lasting troche containing guar gum |
| US3629393A (en) * | 1969-09-11 | 1971-12-21 | Nikken Chemicals Co Ltd | Release-sustaining-tablet |
| US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| US3721735A (en) * | 1970-07-15 | 1973-03-20 | C Thiffault | Compositions for and method of lowering cholesterol levels |
| US3806601A (en) * | 1970-11-18 | 1974-04-23 | Egyt Gyogyszervegyeszeti Gyar | Cholesterol- and lipoid-lowering therapeutical agent |
| US3709991A (en) * | 1970-11-23 | 1973-01-09 | Hoffmann La Roche | Hypolipidemic method |
| GB1338235A (en) * | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
| US3859437A (en) * | 1972-06-02 | 1975-01-07 | Intellectual Property Dev Corp | Reducing cholesterol levels |
| US3795691A (en) * | 1971-06-23 | 1974-03-05 | American Home Prod | Cholesterol-lowering agents |
| US3773920A (en) * | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
| US3923972A (en) * | 1971-10-12 | 1975-12-02 | Monsanto Co | Method of lowering blood cholesterol level |
| US4237118A (en) * | 1972-03-06 | 1980-12-02 | Howard Alan N | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
| US3951821A (en) * | 1972-07-14 | 1976-04-20 | The Dow Chemical Company | Disintegrating agent for tablets |
| JPS4954572A (en) * | 1972-09-29 | 1974-05-27 | ||
| US3992536A (en) * | 1972-11-11 | 1976-11-16 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing a 1-phenyl-2,2,4,4-C1 -C2 alkyl-3-[4-phenyl of pyridyl)-piperazino]-cyclobutanol-(1) and method of use |
| US3959492A (en) * | 1972-12-08 | 1976-05-25 | Istituto Chemioterapico Italiano | Method for reducing serum blood cholesterol |
| US4180064A (en) * | 1972-12-27 | 1979-12-25 | Alza Corporation | System for delivering agent to environment of use over prolonged time |
| US4034087A (en) * | 1973-12-17 | 1977-07-05 | The Regents Of The University Of Michigan | Pharmaceutical composition and process of treatment |
| US4115550A (en) * | 1973-04-23 | 1978-09-19 | Monsanto Company | Composition for lowering blood cholesterol level |
| US3868416A (en) * | 1973-10-01 | 1975-02-25 | American Cyanamid Co | Hypolipidemic 4-(monoalkylamino)benzoic acid derivatives |
| DE2363511A1 (en) * | 1973-12-20 | 1975-07-10 | Bayer Ag | PYRAZOLE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT |
| US4182902A (en) * | 1973-12-27 | 1980-01-08 | Siegfried Aktiengesellschaft | Novel cholesterol-lowering compounds |
| US3864416A (en) * | 1974-03-18 | 1975-02-04 | Universal Oil Prod Co | Separation of tetra-alkyl substituted aromatic hydrocarbon isomers |
| US3965255A (en) * | 1974-05-01 | 1976-06-22 | E. E. Eljim Ecology Ltd. | Controlled drug releasing preparations |
| US4014987A (en) * | 1974-06-04 | 1977-03-29 | Alza Corporation | Device for delivery of useful agent |
| US4166902A (en) * | 1974-10-14 | 1979-09-04 | Paolo Ferruti | High polymers containing nicotinic acid, process for their preparation and their use |
| IT1044798B (en) * | 1974-10-15 | 1980-04-21 | Ferruti Paolo | HIGH POLYMERS CONTAINING NICOTINIC ACID PROCESS FOR THEIR PREPARATION AND USE |
| US4011339A (en) * | 1975-08-15 | 1977-03-08 | Sandoz, Inc. | Hypolipidemic allene carboxylic acids |
| JPS5231981A (en) * | 1975-08-18 | 1977-03-10 | Takeda Chem Ind Ltd | Microcapsule preparation method |
| US3977404A (en) * | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
| US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4058122A (en) * | 1976-02-02 | 1977-11-15 | Alza Corporation | Osmotic system with laminated wall formed of different materials |
| US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4178387A (en) * | 1976-03-30 | 1979-12-11 | William H. Rorer, Inc. | Method for the treatment of arrhythmia |
| US4203439A (en) * | 1976-11-22 | 1980-05-20 | Alza Corporation | Osmotic system with volume amplifier for increasing amount of agent delivered therefrom |
| US4160452A (en) * | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4169944A (en) * | 1977-09-19 | 1979-10-02 | University Patents, Inc. | Cholesterol biosynthesis inhibitors |
| US4348399A (en) * | 1978-02-02 | 1982-09-07 | American Cyanamid Company | Antiatherosclerotic and hypolipidemic 4-(monoalkylamino)phenyl alkane, alkene and alkyne carbinols, aldehydes, carboxylic acids and derivatives |
| US4283382A (en) * | 1977-12-28 | 1981-08-11 | Eastman Kodak Company | Fluorescent labels comprising rare earth chelates |
| US4211783A (en) * | 1978-03-20 | 1980-07-08 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds |
| US4230878A (en) * | 1978-03-08 | 1980-10-28 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives |
| US4205085A (en) * | 1978-03-09 | 1980-05-27 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds |
| DE2903579A1 (en) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | USE OF ACETYL CARNITINE AND OTHER ACYLDER DERIVATIVES OF CARNITINE FOR THE TREATMENT OF HYPERLIPOPROTEINEMIC AND HYPERLIMPIDAEMIA AND MEDICINAL PRODUCTS |
| DE2903558C2 (en) * | 1978-02-03 | 1994-09-01 | Sigma Tau Ind Farmaceuti | Use of L-carnitine |
| US4318914A (en) * | 1978-03-09 | 1982-03-09 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4305959A (en) * | 1978-03-09 | 1981-12-15 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4310545A (en) * | 1978-03-09 | 1982-01-12 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds |
| DD146547A5 (en) * | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | MEDICINAL RETARDANT SHAPE WITH UNFORGETTABLE POROESEN DIFFUSION SHELLS |
| DE2965855D1 (en) | 1978-09-25 | 1983-08-18 | Farlane Stuart John Mc | Pharmaceutical preparations containing a mollusc extract |
| US4485105A (en) | 1978-10-12 | 1984-11-27 | American Cyanamid Company | Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides |
| US4321268A (en) | 1979-02-08 | 1982-03-23 | Merz & Co. | Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same |
| DE2905979C2 (en) * | 1979-02-16 | 1981-01-22 | Carl-Jacob Gatzen | Use of acetylated, distilled monoglycerides for the treatment of lipid metabolic disorders in humans |
| JPS55153715A (en) * | 1979-05-18 | 1980-11-29 | Nikken Kagaku Kk | Prolonged granule of theophylline |
| US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
| US4357469A (en) * | 1979-06-14 | 1982-11-02 | Forest Laboratories, Inc. | Carrier base material for prolonged release therapeutic compositions |
| US4382143A (en) * | 1979-07-23 | 1983-05-03 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs |
| US4251519A (en) * | 1979-07-30 | 1981-02-17 | Anheuser-Busch, Incorporated | Process for the prevention and reduction of elevated blood cholesterol and triglycerides levels |
| US4248857A (en) * | 1979-08-09 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4353887A (en) * | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| US4568547A (en) | 1979-08-30 | 1986-02-04 | Herschler R J | Solid pharmaceutical compositions comprising MSM and their production |
| US4285951A (en) * | 1979-09-07 | 1981-08-25 | Warner-Lambert Company | 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentyl ester of 3-pyridine carboxylic acid and use as an anti-atherosclerotic agent |
| US4440940A (en) * | 1979-10-17 | 1984-04-03 | American Cyanamid Company | Anti-atherosclerotic agents |
| US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| US4308251A (en) * | 1980-01-11 | 1981-12-29 | Boots Pharmaceuticals, Inc. | Controlled release formulations of orally-active medicaments |
| DE3000979A1 (en) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION |
| US4279898A (en) * | 1980-04-22 | 1981-07-21 | Research Foundation Of The City University Of New York | In vivo inhibitors of cholesterol biosynthesis |
| US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| US4362711A (en) * | 1980-07-11 | 1982-12-07 | Evreka Inc. | Blood cholesterol level reducing agent and method |
| US4291030A (en) * | 1980-07-25 | 1981-09-22 | Unimed, Inc. | Method of lowering blood cholesterol |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4465660A (en) | 1981-04-01 | 1984-08-14 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| US4375468A (en) * | 1981-07-13 | 1983-03-01 | Verex Laboratories, Inc. | Constant order release aspirin composition and method of treating arthritis |
| JPS5839618A (en) | 1981-09-04 | 1983-03-08 | Chugai Pharmaceut Co Ltd | Long-acting laminated tablet |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US4525345A (en) | 1981-12-24 | 1985-06-25 | Verex Laboratories, Inc. | Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4428951A (en) * | 1982-04-22 | 1984-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Long acting pharmaceutical composition |
| FR2525474A1 (en) | 1982-04-26 | 1983-10-28 | Roussel Uclaf | NEW ORAL PHARMACEUTICAL FORM OF CLOMETACIN |
| US4556678A (en) | 1982-06-24 | 1985-12-03 | Key Pharmaceuticals, Inc. | Sustained release propranolol tablet |
| US4457907A (en) | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
| US4452775A (en) * | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4472436A (en) | 1982-12-06 | 1984-09-18 | Neo-Bionics, Inc. | Increasing HDL-cholesterol levels with phenylethylamine derivatives |
| US4522804A (en) | 1983-01-03 | 1985-06-11 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of propranolol |
| US4461759A (en) | 1983-01-03 | 1984-07-24 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of veropamil |
| JPS59155309A (en) | 1983-02-22 | 1984-09-04 | Teijin Ltd | Active type vitamin d3 composition and its preparation |
| US4673405A (en) | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
| US4576604A (en) | 1983-03-04 | 1986-03-18 | Alza Corporation | Osmotic system with instant drug availability |
| DE3435325A1 (en) | 1983-04-09 | 1986-04-17 | Nikken Chemicals Co., Ltd., Tokio/Tokyo | LONG-TERM THEOPHYLLIN TABLET AND METHOD FOR THE PRODUCTION THEREOF |
| DE3314003A1 (en) | 1983-04-18 | 1984-10-18 | Boehringer Ingelheim KG, 6507 Ingelheim | DIVISIBLE TABLET WITH DELAYED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF |
| DE3315877A1 (en) | 1983-05-02 | 1984-11-08 | Merz + Co GmbH & Co, 6000 Frankfurt | N-OXIDES OF PYRIDYL CARBONIC ACID ESTERS, A METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS |
| US4882167A (en) | 1983-05-31 | 1989-11-21 | Jang Choong Gook | Dry direct compression compositions for controlled release dosage forms |
| US4571333A (en) | 1983-06-14 | 1986-02-18 | Syntex (U.S.A.) Inc. | Controlled release naproxen and naproxen sodium tablets |
| US4539198A (en) | 1983-07-07 | 1985-09-03 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range |
| US4690824A (en) | 1983-07-07 | 1987-09-01 | Redi-Rowell, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range |
| US4684516A (en) | 1983-08-01 | 1987-08-04 | Alra Laboratories, Inc. | Sustained release tablets and method of making same |
| JPS6035385A (en) | 1983-08-03 | 1985-02-23 | Hitachi Maxell Ltd | Disk cartridge |
| DE3469343D1 (en) | 1983-08-19 | 1988-03-24 | Nissan Chemical Ind Ltd | Antiatherosclerotic agent |
| US4749575A (en) | 1983-10-03 | 1988-06-07 | Bio-Dar Ltd. | Microencapsulated medicament in sweet matrix |
| US4605666A (en) | 1983-10-24 | 1986-08-12 | Basf Corporation | Process for preparing spray-dried powders containing a water-soluble vitamin and powders prepared thereby |
| US4680323A (en) | 1983-12-01 | 1987-07-14 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
| US4795327A (en) | 1984-03-26 | 1989-01-03 | Forest Laboratories, Inc. | Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants |
| US4849229A (en) | 1984-03-26 | 1989-07-18 | Forest Laboratories, Inc. | Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants |
| US4540566A (en) | 1984-04-02 | 1985-09-10 | Forest Laboratories, Inc. | Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose |
| JPS60209523A (en) | 1984-04-03 | 1985-10-22 | Mitsubishi Petrochem Co Ltd | Antilipemic agent |
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4603142A (en) | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
| US4713245A (en) | 1984-06-04 | 1987-12-15 | Mitsui Toatsu Chemicals, Incorporated | Granule containing physiologically-active substance, method for preparing same and use thereof |
| JPS6124516A (en) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | Long active tablet |
| US4610870A (en) | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4678516A (en) | 1984-10-09 | 1987-07-07 | The Dow Chemical Company | Sustained release dosage form based on highly plasticized cellulose ether gels |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4747881A (en) | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| FR2578423B1 (en) | 1985-03-06 | 1988-12-30 | Grimberg Georges | GUAR GUM-BASED PHARMACEUTICAL COMPOSITION FOR THE PROTECTION OF THE OESO-GASTRO-DUODENAL MUCOSA |
| US4657757A (en) | 1985-03-29 | 1987-04-14 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
| US4695591A (en) | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
| CA1279574C (en) | 1985-04-17 | 1991-01-29 | Jeffrey L. Finnan | Process for lubricating water-soluble vitamin powders |
| EP0207638B1 (en) | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
| FR2585246A1 (en) | 1985-07-26 | 1987-01-30 | Cortial | PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE |
| GB8521494D0 (en) | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
| US4710519A (en) | 1985-09-30 | 1987-12-01 | Basf Corporation | Process for preparing spray dried acetaminophen powder and the powder prepared thereby |
| CA1259915A (en) | 1985-10-09 | 1989-09-26 | Sailen S. Mookerjea | Means to reduce plasma cholesterol |
| IT1187750B (en) | 1985-10-15 | 1987-12-23 | Eurand Spa | PROCEDURE FOR THE PREPARATION OF TABLETS, EVEN OF PROLONGED RELEASE, OF ISCSORBIDE-5-MONONITRATE STABILIZED AND FORMULATIONS SO OBTAINED |
| US4753801A (en) | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
| US4734285A (en) | 1985-10-28 | 1988-03-29 | The Dow Chemical Company | Sustained release compositions |
| JPS62106019A (en) | 1985-11-01 | 1987-05-16 | Terumo Corp | Anti-hyperlipemic agent |
| US4704285A (en) | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
| DE3541428A1 (en) | 1985-11-23 | 1987-05-27 | Hoechst Ag | NEW BASICALLY SUBSTITUTED PYRIDINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCTS CONTAINING IT AND THEIR USE |
| US4696762A (en) | 1985-12-06 | 1987-09-29 | Zumbro Enterprises, Inc. | Hydroxypropylmethylcellulose |
| IT1188212B (en) | 1985-12-20 | 1988-01-07 | Paolo Colombo | SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES |
| IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
| US4837032A (en) | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
| IT1191674B (en) | 1986-03-07 | 1988-03-23 | Eurand Spa | FORMULATIONS FOR THE PREPARATION OF PROLONGED-RELEASE DRUGS SUITABLE FOR ORAL ADMINISTRATION |
| US4775535A (en) | 1986-04-04 | 1988-10-04 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
| US4855143A (en) | 1986-04-04 | 1989-08-08 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
| SE8601624D0 (en) | 1986-04-11 | 1986-04-11 | Haessle Ab | NEW PHARMACEUTICAL PREPARATIONS |
| US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| DE3614019A1 (en) | 1986-04-25 | 1987-11-05 | Degussa | METHOD FOR PRODUCING HIGH PURITY CRYSTAL CRYSTALLINE NICOTINIC ACID |
| US4795642A (en) | 1986-05-01 | 1989-01-03 | Pharmacaps, Inc. | Gelatin-encapsulated controlled-release composition |
| US4708834A (en) | 1986-05-01 | 1987-11-24 | Pharmacaps, Inc. | Preparation of gelatin-encapsulated controlled release composition |
| US4752479A (en) | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US4946870A (en) | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
| US4824672A (en) | 1986-06-06 | 1989-04-25 | Hauser-Kuhrts, Inc. | Method and composition for reducing serum cholesterol |
| IT1200178B (en) | 1986-07-23 | 1989-01-05 | Alfa Farmaceutici Spa | GALENIC FORMULATIONS WITH SCHEDULED SALE CONTAINING DRUGS WITH ANTI-FLOGISTIC ACTIVITY |
| CH668187A5 (en) | 1986-08-07 | 1988-12-15 | Ciba Geigy Ag | THERAPEUTIC SYSTEM WITH SYSTEMIC EFFECT. |
| US4814354A (en) | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
| US4851233A (en) | 1986-10-06 | 1989-07-25 | Warner-Lambert Company | Sustained release formulations |
| GB8628359D0 (en) | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
| US4824677A (en) | 1986-12-18 | 1989-04-25 | The Unjohn Company | Grooved tablet for fractional dosing of sustained release medication |
| ATE72111T1 (en) | 1987-01-14 | 1992-02-15 | Ciba Geigy Ag | THERAPEUTIC SYSTEM FOR POORLY SOLUBLE ACTIVE INGREDIENTS. |
| US4744907A (en) | 1987-01-16 | 1988-05-17 | Interferon Sciences, Inc. | Blood cell separation |
| JP2547995B2 (en) | 1987-01-26 | 1996-10-30 | 昭和電工株式会社 | Granules for ruminants and method for producing the same |
| US5015479A (en) | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
| US4851232A (en) | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
| US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
| US4789549A (en) | 1987-03-09 | 1988-12-06 | Warner-Lambert Company | Sustained release dosage forms |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| KR960011236B1 (en) | 1987-05-08 | 1996-08-21 | 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 | Pharmaceutical compositions of cimetidine |
| GB8710965D0 (en) | 1987-05-08 | 1987-06-10 | Smith Kline French Lab | Pharmaceutical compositions |
| JPS63310827A (en) * | 1987-06-15 | 1988-12-19 | Sanwa Kagaku Kenkyusho Co Ltd | Sustained release pharmaceutical containing nicotinic aid derivative as principal agent |
| DE3720757A1 (en) | 1987-06-24 | 1989-01-05 | Bayer Ag | DHP COAT TABLET |
| US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
| DE3721721C1 (en) | 1987-07-01 | 1988-06-09 | Hoechst Ag | Process for coating granules |
| FR2618073B1 (en) | 1987-07-16 | 1990-09-07 | Pf Medicament | HYDROPHILIC MATRIX-TYPE TABLETS BASED ON SALBUTAMOL AND THEIR PREPARATION METHOD |
| US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4795644A (en) | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
| US4814183A (en) | 1987-08-31 | 1989-03-21 | Merck & Co., Inc. | Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins |
| US4994276A (en) | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| IE60311B1 (en) | 1987-09-24 | 1994-06-29 | American Home Prod | Sustained release etodolac |
| SE8703881D0 (en) | 1987-10-08 | 1987-10-08 | Haessle Ab | NEW PHARMACEUTICAL PREPARATION |
| EP0513874B1 (en) | 1987-10-09 | 1996-07-10 | KOTOBUKI & CO., LTD. | Writing tool |
| US5023245A (en) | 1987-11-10 | 1991-06-11 | Hauser-Kuhrts, Inc. | Improved niacin formulation |
| US4965252A (en) | 1988-06-28 | 1990-10-23 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination compositions of guar gum and niacin |
| US4911917A (en) | 1988-06-28 | 1990-03-27 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination comopsitions of magnesium salt and niacin |
| US4946963A (en) | 1987-11-13 | 1990-08-07 | The University Of North Carolina At Chapel Hill | Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones |
| US5211958A (en) | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US4983398A (en) | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
| US5178854A (en) | 1988-03-24 | 1993-01-12 | Taisho Pharmaceutical Co., Ltd. | Cholesterol-lowering agents |
| DE3812402A1 (en) | 1988-04-14 | 1989-10-26 | Basf Ag | METHOD FOR THE PRODUCTION OF WATER-SOLUBLE COPOLYMERISATS BASED ON MONOETHYLENICALLY UNSATURATED CARBONIC ACIDS AND THE USE THEREOF |
| US5096714A (en) | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| US4866058A (en) | 1988-07-27 | 1989-09-12 | Izydore Robert A | Method for control of hyperlipidemia |
| US5034528A (en) | 1988-07-27 | 1991-07-23 | North Carolina Central University | Compositions for the control of hyperlipidemia |
| US5196440A (en) | 1988-07-29 | 1993-03-23 | Zambon Group S.P.A. | Compounds active as inhibitors of the cholesterol biosynthesis |
| US5169639A (en) | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| US4999380A (en) | 1988-10-18 | 1991-03-12 | Nestec S.A. | Treatment of lipoprotein disorders associated with cholesterol metabolism |
| US4920123A (en) | 1988-10-21 | 1990-04-24 | Beyer Jr Karl H | Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals |
| US5110817A (en) | 1988-10-21 | 1992-05-05 | Beyer Jr Karl H | Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals |
| US4997658A (en) | 1988-11-21 | 1991-03-05 | Merck & Co., Inc. | Method for enhancing the lowering of plasma cholesterol levels |
| US5260305A (en) | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
| US5039341A (en) | 1988-12-19 | 1991-08-13 | The Dow Chemical Company | Binder composition comprises a blend of a high viscosity and low viscosity hydroxypropyl methylcellulose ether, and a tape joint composition containing such binder |
| US4920115A (en) | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
| US4970081A (en) | 1989-01-03 | 1990-11-13 | Sterling Drug Inc. | Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith |
| US5032406A (en) | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
| JP2664238B2 (en) | 1989-03-01 | 1997-10-15 | 日清製粉株式会社 | Nicotinic acid or its ester derivatives |
| US5268181A (en) | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5264226A (en) | 1989-07-12 | 1993-11-23 | Roquette Freres | Process for preparing dairy products with a low content of sterols, particularly of cholesterol |
| US5262165A (en) | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
| DK469989D0 (en) | 1989-09-22 | 1989-09-22 | Bukh Meditec | PHARMACEUTICAL PREPARATION |
| US5171570A (en) | 1989-12-08 | 1992-12-15 | Lotte Company Limited | Substance having suppressing function for diseases relating to increase in cholesterol, and foods and drinks in which it is used |
| US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| US5190940A (en) | 1990-09-14 | 1993-03-02 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
| US5130333A (en) | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
| US5190970A (en) | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| US5286736A (en) | 1990-11-22 | 1994-02-15 | Dr. Karl Thomae Gmbh | Pyridyl compounds and pharmaceutical compositions containing these compounds |
| GB9100437D0 (en) | 1991-01-09 | 1991-02-20 | Glaxo Group Ltd | Chemical compounds |
| US5145678A (en) | 1991-01-22 | 1992-09-08 | Dusko Gakic | Method of reducing blood serum cholesterol |
| US5182298A (en) | 1991-03-18 | 1993-01-26 | Merck & Co., Inc. | Cholesterol lowering agents |
| US5256689A (en) | 1991-05-10 | 1993-10-26 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| US5262435A (en) | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5167964A (en) | 1992-02-14 | 1992-12-01 | Warner-Lambert Company | Semi-enteric drug delivery systems and methods for preparing same |
| US5258401A (en) | 1992-07-10 | 1993-11-02 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| US6080428A (en) * | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| EP2319513A1 (en) * | 1993-09-20 | 2011-05-11 | Abbott Respiratory LLC | Nicotinic acid compositons for treating hyperlipidemia and related methods therefor |
| US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| AU5787996A (en) * | 1995-04-19 | 1996-11-07 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
-
1997
- 1997-03-06 US US08/814,974 patent/US6129930A/en not_active Expired - Lifetime
-
1998
- 1998-03-06 AU AU63481/98A patent/AU6348198A/en not_active Abandoned
- 1998-03-06 AT AT98910260T patent/ATE289197T1/en not_active IP Right Cessation
- 1998-03-06 DE DE69829042T patent/DE69829042T2/en not_active Expired - Lifetime
- 1998-03-06 CA CA002283322A patent/CA2283322C/en not_active Expired - Lifetime
- 1998-03-06 EP EP98910260A patent/EP0966284B1/en not_active Expired - Lifetime
- 1998-03-06 BR BR9815457-5A patent/BR9815457A/en not_active Application Discontinuation
- 1998-03-06 WO PCT/US1998/004590 patent/WO1998039002A1/en active Application Filing
- 1998-03-06 CA CA002591710A patent/CA2591710A1/en not_active Abandoned
- 1998-03-06 EP EP98907745A patent/EP0969837A1/en not_active Ceased
- 1998-03-06 ES ES98910260T patent/ES2234100T3/en not_active Expired - Lifetime
- 1998-03-06 BR BR9815454-0A patent/BR9815454A/en not_active Application Discontinuation
- 1998-03-06 AU AU64545/98A patent/AU6454598A/en not_active Abandoned
- 1998-03-06 CA CA002283159A patent/CA2283159C/en not_active Expired - Lifetime
- 1998-03-06 WO PCT/US1998/004578 patent/WO1998039001A1/en active IP Right Grant
-
1999
- 1999-09-02 NO NO994275A patent/NO994275L/en not_active Application Discontinuation
- 1999-09-02 NO NO994248A patent/NO994248L/en not_active Application Discontinuation
- 1999-09-06 FI FI991895A patent/FI119910B/en not_active IP Right Cessation
- 1999-09-06 FI FI991896A patent/FI19991896A/en not_active Application Discontinuation
- 1999-12-22 US US09/470,603 patent/US7011848B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2283159A1 (en) | 1998-09-11 |
| FI19991895A (en) | 1999-09-22 |
| NO994275D0 (en) | 1999-09-02 |
| BR9815454A (en) | 2001-10-23 |
| AU6454598A (en) | 1998-09-22 |
| DE69829042T2 (en) | 2006-05-04 |
| EP0966284B1 (en) | 2005-02-16 |
| NO994275L (en) | 1999-10-11 |
| EP0966284A1 (en) | 1999-12-29 |
| BR9815457A (en) | 2001-10-16 |
| NO994248D0 (en) | 1999-09-02 |
| WO1998039002A1 (en) | 1998-09-11 |
| WO1998039001A1 (en) | 1998-09-11 |
| CA2283322A1 (en) | 1998-09-11 |
| NO994248L (en) | 1999-10-20 |
| US6129930A (en) | 2000-10-10 |
| AU6348198A (en) | 1998-09-22 |
| EP0969837A1 (en) | 2000-01-12 |
| ES2234100T3 (en) | 2005-06-16 |
| CA2283322C (en) | 2007-06-19 |
| ATE289197T1 (en) | 2005-03-15 |
| FI119910B (en) | 2009-05-15 |
| FI19991896A (en) | 1999-09-22 |
| DE69829042D1 (en) | 2005-03-24 |
| US7011848B1 (en) | 2006-03-14 |
| CA2591710A1 (en) | 1998-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2283159C (en) | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | |
| US20070225341A1 (en) | Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor | |
| US20120245207A1 (en) | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | |
| US6818229B1 (en) | Intermediate release nicotinic acid compositions for treating hyperlipidemia | |
| US6746691B2 (en) | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics | |
| US20130005779A1 (en) | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics | |
| US20030157153A1 (en) | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics | |
| US20110301207A1 (en) | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia | |
| AU775967B2 (en) | Starter kit containing nicotinic acid compositions | |
| CA2574987A1 (en) | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor | |
| AU4751702A (en) | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDC | Discontinued application reinstated | ||
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180306 |
|
| MKEX | Expiry |
Effective date: 20180306 |